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Abstract 
Background: Chronic kidney disease (CKD) and cancer are major public health 
problems in the elderly population. With the development of cancer screening and 
efficacious treatments including chemotherapy, the number of cancer survivors has been 
increasing. In elderly cancer patients, little information is available on CKD as a late 
effect of chemotherapy or on risk of acute kidney injury (AKI) associated with 
chemotherapy. Furthermore, little is known about patterns of clinical practice regarding 
renal function monitoring in this population after completion of cancer treatment, 
especially patients treated with potential nephrotoxic chemotherapeutic agents.  
 
Objectives: The purpose of this study was to evaluate the association between 
adjuvant chemotherapy (CHEMO) and risks of AKI and CKD and rate of renal function 
monitoring in elderly women diagnosed with early stage breast cancer. 
 
Methods: The study was a 1:1 individually matched, retrospective cohort design 
including women diagnosed with stages I-III breast cancer at ages 66-89 years 1992-2007 
in Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data. 
Sequential matching on time-dependent propensity score at the day of CHEMO initiation 
was performed. Follow-up (F/U) began on the CHEMO initiation date of the treated 
patient for each matched pair. AKI was identified in the first 6 months of F/U, while 
CKD and renal function monitoring were examined until December 31, 2009. The 
associations between CHEMO and risks of AKI and CKD were evaluated using Cox 
proportional hazards models. The associations between CHEMO and rate of renal 
function monitoring was examined using interval Poisson regression models with the 
cutoffs of F/U intervals ≤ 1 year, > 1-≤ 2 years, and > 2-< 18 years. 
 
Results: A total of 28,048 patients were included in the matched study cohorts. 
CHEMO was associated with a 2.7-fold increased risk of AKI within 6 months after 
initiation (HR 2.7, 95% CI 1.8-4.1), despite a very low overall incidence rate (16 and 6 
per 1,000 person-years in patients treated with CHEMO and not treated, respectively). To 
find a possible explanation to this association, distribution of other diseases coded on 
hospital claims in AKI patients was examined and showed that septicemia occurred in 
40% of CHEMO treated patients with AKI and in only 17% of untreated patients with 
AKI. No significant association was found between CHEMO and risk of CKD in the 
maximum 18-year follow-up (HR 1.00, 95% CI 0.93-1.07). The rate of urine albumin 
testing was low, ranging from 59/1,000 person-years in the first year of F/U for untreated 
patients to 94/1,000 person-years after 2 years of F/U for treated patients. In the first and 
second year F/U, no significant differences were found in rate of testing in CHEMO 
treated patients compared with untreated patients (RR 1.00, 95% CI 0.86-1.18 in first 
year F/U; RR 1.07, 95% CI 0.92-1.25 in second year F/U). After 2 years of F/U, rate of 
urine albumin testing was 12% higher in treated patients (RR 1.12, 95% CI 1.03-1.20). 
 
  iv 
Conclusion: CHEMO is associated with increased risk of AKI. This association 
may be partially explained by septicemia caused by infection/neutropenia due to use of 
myelosuppressive chemotherapeutic agents, which highlights the importance of 
preventing serious complications of CHEMO in preventing AKI. The findings of no 
association between CHEMO and risk of CKD do not suggest a late nephrotoxic effect of 
chemotherapeutic agents commonly used to treat breast cancer in the adjuvant setting, or 
provide evidence for the need for a clinical practice guideline for CKD screening 
specifically in elderly breast cancer patients treated with CHEMO. Future studies on 
CKD as a late effect of cancer treatment for other solid tumors commonly treated with 
known or potential nephrotoxic agents are warranted.  
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Chapter 1 Introduction 
Chronic kidney disease (CKD) is a major worldwide public health problem.1;2 In 
the United States, CKD prevalence increased from 10% based on National Health and 
Nutrition Examination Surveys (NHANES) 1988-1994 to 13% based on NHANES 1999-
2004. Approximately 26 million adults currently have CKD.3 In 2012, the United States 
Renal Data System (USRDS) reported that the prevalence of recognized CKD in the 
Medicare population aged 65 years or older increased from 2.7% in 2000 to 9.2% in 2010 
(Figure 2.2, p.55).4 Cardiovascular disease, premature death, and kidney failure are the 
three primary adverse consequences of CKD.1;5-8 
CKD is also common in adult patients with cancer.4;9 As the U.S. population 
continues to age, the number of newly diagnosed elderly cancer patients will expand. 
Chemotherapy has been recognized to be efficacious in cancer treatment and its use has 
been increasing over the past several decades. Although they benefit patients overall, 
chemotherapeutic drugs can damage healthy cells along with cancerous cells, causing 
side effects. Some common side effects associated with chemotherapy generally resolve 
when the treatment ends. However, organ damage and functional disabilities caused by 
the disease, the treatment, or both may occur months or years after the treatment is 
completed. With the development of effective cancer screening and treatment, many 
patients with cancers are cured and live for extended periods of time after the completion 
of treatment. Many studies have shown that chemotherapeutic agents are associated with 
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a wide range of late effects such as cardiotoxicity,12-17 pulmonary toxicity,18-20 cognitive 
dysfunction and neurotoxicity,21-25 and other chronic conditions.26-36  
Studies of CKD as a late effect of chemotherapy are available,37-42 but have 
mainly focused on childhood cancer survivors. Few studies in the literature have 
evaluated the incidence of CKD and the association between chemotherapy and risk of 
CKD in elderly cancer patients. Additionally, since renal function is expected to 
deteriorate with increasing age,43 elderly cancer patients receiving chemotherapy 
treatment may have an increased risk of acute kidney injury (AKI), which could be 
precipitated by drug toxicity or complications from infections. Although AKI induced by 
chemotherapeutic agents has been extensively investigated, most studies have been 
limited to case reports, small cohort studies, or clinical trials.44-50 Because elderly cancer 
patients are usually underrepresented in clinical trials, little information is available on 
the occurrence of AKI as an adverse outcome of chemotherapy treatment in elderly 
cancer patients. To date, no population-based study has estimated the incidence of AKI 
and the magnitude of association between nephrotoxic chemotherapeutic agents and the 
risk of AKI in elderly cancer patients. Furthermore, clinical practice guidelines for 
chemotherapy treatment recommend that renal function be assessed prior to each cycle 
for potential dose modification to avoid myelosuppression from several known 
nephrotoxic agents.51 For surveillance and management of nephrotoxicity among cancer 
survivors, however, the clinical practice guidelines are available only for asymptomatic 
pediatric cancer survivors. There is currently no guideline for surveillance and 
management of nephrotoxicity in adult cancer survivors. Little is known about patterns of 
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clinical practice regarding renal function monitoring in elderly cancer patients after 
completion of cancer treatment, especially patients treated with nephrotoxic 
chemotherapeutic agents.  
I conducted three retrospective cohort studies to evaluate the association between 
adjuvant chemotherapy and risk of AKI and CKD and rate of renal function monitoring 
among elderly women with breast cancer. I chose breast cancer for my dissertation based 
on the following considerations. First, breast cancer is one of the most commonly 
occurring cancers in the U.S., with over 207,090 new diagnoses reported in 2010.52 
Second, breast cancer has a high survival rate, representing the largest proportion of 
female cancer survivors (41%), and of all cancer survivors (22%), on January 1, 2008.53 
Finally, evidence regarding the nephrotoxicity of chemotherapeutic agents commonly 
used in the treatment of breast cancer is lacking. 
The current study addresses three primary objectives and two secondary 
objectives: 
Primary objectives: 
1. To examine whether adjuvant chemotherapy is associated with increased risk of 
AKI during the treatment period among elderly breast cancer patients.  
2. To evaluate whether adjuvant chemotherapy is associated with increased risk of 
CKD among elderly breast cancer patients.   
3. To compare the use of laboratory tests to monitor kidney function during the 
post-treatment period among elderly breast cancer patients treated with adjuvant 
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chemotherapy with the use of these tests among patients not treated with adjuvant 
chemotherapy. 
Secondary objectives: 
1. To examine whether the strength of association between adjuvant 
chemotherapy and risk of AKI during the treatment period varies among major types of 
chemotherapy regimens in elderly women with breast cancer.  
2. To evaluate whether the strength of association between adjuvant 
chemotherapy and risk of CKD varies among major types of chemotherapy regimens in 
elderly women with breast cancer.  
These objectives were accomplished through the use of the linked Surveillance, 
Epidemiology and End-Results (SEER)-Medicare data. 
The rest of the thesis is organized into five chapters. Chapter 2 presents a 
literature review of chemotherapy-related nephrotoxicity and the significance of the 
proposed study. In this chapter, I first focus on chemotherapy, describing the 
classification of chemotherapeutic agents, factors related to use of chemotherapy, and 
toxicities. Then, I move on to nephrotoxicity, describing its definition, clinical 
manifestations focusing on AKI and CKD, pathogenesis, and current literature on 
chemotherapy-induced nephrotoxicity. Next, I briefly describe the clinical practice 
guidelines for surveillance and management of nephrotoxicity. I conclude Chapter 2 by 
discussing the significance of the proposed study. Chapter 3 describes the study designs 
and analytical methods to address each objective. Chapter 4 presents the study findings. 
Chapter 5 summarizes and interprets the main study findings, discusses the strength and 
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limitations of the study, discusses the implications, and proposes two future research 
ideas. Finally, Chapter 6 presents the conclusions. 
  
 6 
 
Chapter 2 Literature Review  
2.1 Chemotherapy  
2.1.1 Definition 
Chemotherapy is a type of cancer treatment that uses a single drug or 
combinations of drugs to slow or stop the rapid growth of cancer cells by impacting cell 
division. Depending on the type and stage of the cancer, chemotherapy can be used prior 
to surgery to shrink a tumor enough to make surgical removal possible (neoadjuvant 
therapy) or after surgery, alone or coupled with radiation therapies, to destroy any 
undetected cancer cells that may have migrated to other parts of the body (adjuvant 
therapy). Sometimes, chemotherapy is administered to manage the pain or pressure 
caused by cancer (palliative care).  
2.1.2 Classification of Chemotherapeutic Agents 
Chemotherapeutic agents can be classified into the following groups based on 
their mechanisms:  
1) Alkylating agents directly damage DNA to prevent the cancer cell from 
reproducing. These agents attach an alkyl group, resulting in linking nucleobases in the 
DNA double helix, which prevents DNA replication and cell division. These agents work 
in all phases of the cell cycle. Examples include cisplatin, carboplatin, cyclophosphamide 
(Cytoxan®), and ifosfamide. Of these alkylating agents, cyclophosphamide, coupled with 
two other agents, is commonly used in breast cancer treatment in the adjuvant setting. 
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2) Anti-metabolites interfere with DNA and RNA growth by substituting for the 
normal building blocks of RNA and DNA. These agents damage cells during the S phase. 
Examples used in breast cancer treatment include 5-fluorouracil (5-FU) and 
methotrexate.  
3) Anti-tumor antibiotics interfere with enzymes involved in DNA replication. 
These agents work in all phases of the cell cycle and are widely used for a variety of 
cancers. Examples used in breast cancer treatment include doxorubicin (Adriamycin®) 
and epirubicin.  
4) Plant alkaloids are plant-derived chemicals that can stop or inhibit enzymes 
from making proteins needed for cell reproduction. These drugs work during the M phase 
of the cell cycle, but can damage cells in all phases. Thus, they are used to treat many 
different types of cancer including breast, lung, myelomas, lymphomas, and leukemias. 
Examples used in breast cancer treatment include the taxanes (paclitaxel and docetaxel). 
2.1.3 Factors Related to Use of Chemotherapy      
In general, the type and stage of cancer, previous treatment with chemotherapy, 
and comorbid conditions (diabetes or heart disease) determine the use of chemotherapy. 
Patients with pre-existing CKD may need dose adjustment for nephrotoxic agents. 
Morimoto et al showed that factors related to increased likelihood of receiving 
chemotherapy in women with breast cancer include younger age, white race, good 
general health and few comorbid conditions, more severe clinical disease, good response 
to previous treatment, and breast cancer that is estrogen or progesterone receptor 
negative.54 
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2.1.4 Toxicities 
Although they benefit patients overall, chemotherapeutic drugs can damage 
healthy cells along with cancerous cells, causing side effects. The most common side 
effects associated with chemotherapy include hair loss, fatigue, nausea, and vomiting, 
which generally resolve when the treatment ends. However, the organ damage and 
functional disabilities caused by the disease, the treatment, or both may occur months or 
years after the treatment is completed. With advances in the early diagnosis and effective 
treatment of cancer, many cancer patients are either cured of their cancer or live with it as 
a chronic disease.55-58 Patients who survived the initial cancer treatments are likely to 
experience the late consequences of these treatments. 
Many studies have shown that chemotherapeutic agents are associated with a 
wide range of late effects such as cardiotoxicity,12-17 pulmonary toxicity,18-20 
nephrotoxicity,37-42 cognitive function and neurotoxicity,21-25 premature menopause,26 
sexual impairment,27;28 infertility,29 chronic fatigue,30;31 and second malignancies.32-34 In 
addition, significant adverse psychosocial outcomes after the completion of treatment 
occur in many survivors and their families, affecting quality of life.35;36 
2.2 Nephrotoxicity 
2.2.1 Definition 
Nephrotoxicity is the development of functional or structural kidney damage 
caused by toxic chemicals, medications, or other treatments.59 The damage in kidney 
function includes glomerular or tubular dysfunction, impairment of blood pressure 
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control, and renal endocrine dysfunction. The damage in kidney structure includes 
microscopic morphologic lesions such as glomerular or tubular abnormalities and gross 
morphologic lesions such as the small (atrophic) kidneys associated with chronic renal 
failure. 
The kidneys are a pair of vital organs that regulate the volume, osmolarity, 
electrolyte content, concentration, and acidity of body fluids; excrete metabolic end 
products, mostly urea and creatinine; eliminate foreign substances, such as drugs and 
toxic substances; and release three important hormones: 1) renin, which regulates blood 
pressure; 2) erythropoietin, which stimulates the bone marrow to make red blood cells; 
and 3) calcitriol, the active form of vitamin D, which helps maintain the calcium and 
phosphate balance in the body.60 
The kidneys are often exposed to potential toxic insults because urinary excretion 
is one of the major routes of elimination of many chemotherapeutic agents and their 
metabolites. Therefore, patients with cancer are frequently at risk for renal dysfunction 
either related to the malignancy itself or to its treatment. Some kidney damage is transient 
and reversible after the treatment ends, but high doses of certain chemotherapy agents or 
prolonged use of standard doses may cause permanent damage.  
2.2.2 Clinical Manifestations 
Nephrotoxicity induced by chemotherapeutic agents may manifest itself as 
tubulopathies, AKI, nephritic/nephrotic syndrome, and CKD. Only AKI and CKD are 
discussed. 
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2.2.2.1 Acute Kidney Injury 
Definition  
AKI (formerly referred to as acute renal failure) is a complex disorder that can be 
acquired in both community and hospital settings with clinical manifestations ranging 
from a relatively modest increase in serum creatinine level to anuric renal failure 
requiring dialysis. The definition of AKI varies widely in published studies in which AKI 
is defined based on serum creatinine changes, absolute levels of serum creatinine, 
changes in blood urea nitrogen or urine output, or the need for dialysis.61 In the absence 
of a standard definition, AKI is generally defined as an abrupt and sustained decline in 
glomerular filtration rate (GFR) with or without a decrease in urine output occurring over 
hours or days.62  
Staging/classification 
In 2004, the Acute Dialysis Quality Initiative (ADQI) group published a 
classification system for AKI to establish a uniform definition. AKI is classified in five 
categories (Table 1), including three degrees of increasing severity based on changes in 
serum creatinine levels within 1 to 7 days or urine output within 48 hours (risk, injury, 
and failure) and two clinical outcomes (loss and end-stage disease), known as the RIFLE 
criteria.63 AKI is both abrupt (within 1-7 days) and sustained (more than 24 hours). 
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Table 2-1 Risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification 
for acute kidney injury 
Category  Serum Creatinine Level or Renal Function Urine Output  
Risk Increased serum creatinine 1.5 times 
baseline  
< 0.5mL/kg/hour for more than 
6 hours 
Injury 2 times baseline < 0.5mL/kg/hour for more than 
12 hours 
Failure 3 times baseline, or serum creatinine level at 
least 4 mg/dL [354 μmol/l] with absolute 
increase exceeding 0.5 mg/dL [44 μmol/l] 
< 0.3mL/kg/hour for more than 
24 hours, or anuria for more 
than 12 hours 
Loss Complete loss of kidney function for longer than 4 weeks 
End-stage End-stage kidney disease for longer than 3 months 
(Note: adapted from Figure 1, p. R206)63  
 
In 2007, the Acute Kidney Injury Network (AKIN) recommended a modified 
diagnostic criteria and staging system for AKI based on accumulating evidence that small 
increments in serum creatinine are associated with adverse outcomes.64 AKI is defined by 
an abrupt (within 48 hours) reduction in kidney function currently defined as an absolute 
increase in serum creatinine of ≥ 0.3 mg/dL (≥ 26.4 μmol/L), a percentage increase in 
serum creatinine of ≥ 50% (1.5-fold from baseline), or a reduction in urine output 
(documented oliguria of less than 0.5 mL/kg per hour for more than 6 hours). Based on 
this definition, AKIN modified the RIFLE criteria so that patients meeting the proposed 
definition of AKI could be staged (Table 2-2). This new classification system removed 
the “loss” and “failure” categories from the RIFLE criteria and retained them as 
outcomes. The new system also proposed the diagnosis of AKI based on changes in 
serum creatinine over the course of 48 hours, instead of 1 week as in the RIFLE criteria. 
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Table 2-2 AKIN classification/staging system for acute kidney injury 
Stage Serum Creatinine Criteria Urine Output Criteria 
1 Increase in serum creatinine to ≥ 0.3 mg/dL 
(26.4 μmol/l) or increase to ≥ 150% to 200% 
(1.5- to 2-fold) from baseline 
< 0.5 mL/kg per hour for 
more than 6 hours 
2 Increase in serum creatinine to > 200% to 
300% (2- to 3-fold) from baseline 
< 0.5 mL/kg per hour for 
more than 12 hours 
3 Increase in serum creatinine to > 300% (3-
fold) from baseline (or serum creatinine ≥ 4.0 
mg/dL [≥ 354 μmol/l] with an acute increase 
of at least 0.5 mg/dL [44 μmol/l]) 
< 0.3 mL/kg per hour for 24 
hours or anuria for 12 hours 
 (Note: adapted from Table 2)64 
Epidemiology 
AKI is a complex disorder and a serious complication of many disease and 
treatments. The incidence of AKI varies greatly depending on the clinical settings, 
ranging from 1% in patients at admission to the hospital, to 2% to 5% during the 
hospitalization, and up to 4% to 15% after cardiopulmonary bypass.65 Multiple studies 
have shown that AKI is more common in the elderly population, and incidence of AKI 
increases with older age.66-69 In 2012, the USRDS reported that the rates of 
hospitalization for first AKI in 2010 for Medicare patients age 66-69, 70-74, 75-79, 80-
84, and 85 years and older were 13.6, 18.1, 24.9, 34.2, and 46.9 per 1,000 patient years, 
respectively (Figure 6.3, p.100).4 AKI is also common in cancer patients. Data from 
several studies of critically ill cancer patients demonstrated that the incidence of AKI 
ranged from 12% to 49% during the intensive care unit stay, and 9% to 32% required 
dialysis.70 AKI induced by chemotherapeutic agents is discussed in detail in Section 
2.2.4.1. 
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Causes 
The multiple causes of AKI can be classified as prerenal, intrinsic, or postrenal 
according to the underlying pathophysiology, presented in Figure 2-1. 
 
Figure 2-1 Main categories of acute kidney injury 
 
 (Note: adapted from Figure 1, p. 45971 and Figure 1, p.144965). 
Prerenal AKI is usually caused by any reduction in blood flow to the kidneys and 
represents 40% to 80% of cases.72;73 Diseases that may cause prerenal AKI in the 
outpatient setting include vomiting, diarrhea, poor fluid intake, fever, use of diuretics, 
and heart failure. Hospital-acquired prerenal AKI is often due to cardiac failure, liver 
dysfunction, cardiac surgery, or septic shock.65 Since the renal parenchyma typically 
Acute Kidney 
Injury 
Prerenal 
causes Intrinsic causes 
Acute tubular 
necrosis (ATN) 
Ischemia Toxins 
Acute 
interstitial 
nephritis (AIN) 
Vascular 
disease 
Glomerular 
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Postrenal 
causes 
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remains intact, renal function returns to normal if the underlying cause has been 
corrected.  
Postrenal AKI results from mechanical obstruction of the urinary outflow tract 
distal to the bladder and represents 5% to 15% of cases.72;73 Postrenal AKI is often 
present in the outpatient setting and is most commonly caused by prostatic hypertrophy; 
cancers of cervix, prostate, bladder, or colon; and kidney stones.65 It is crucial to identify 
and correct the causes of postrenal AKI quickly because the duration of obstruction 
negatively affects the potential for recovery of renal function.74 
Intrinsic or intrarenal AKI refers to any injuries affecting renal parenchyma and 
represents 10% to 30% of cases.72;73 According to the area of kidney parenchyma 
involved, intrinsic AKI can be further categorized into four groups: acute tubular necrosis 
(ATN), acute interstitial nephritis, vascular disease, and glomerular disease. ATN is the 
most common cause of intrinsic AKI and usually occurs after an acute ischemic or toxic 
event. Many clinical conditions can cause generalized or localized reduction in renal 
blood flow leading to ischemic ATN; these include sepsis, small-vessel renal vascular 
disease, large-vessel renal vascular disease, intravascular volume depletion and 
hypotension, decreased effective intravascular volume, medications, and hepatorenal 
syndrome.65 Of these conditions, sepsis is the most frequent cause of ischemic ATN. 
Toxic ATN results from direct tubular damage from nephrotoxins such as 
aminoglycoside antibiotic, radio-contrast agents, chemotherapeutic agents, and other 
drugs. Acute interstitial nephritis is most often caused by an allergic reaction to a drug75 
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and accounts for approximately 2% to 3% of AKI.71 Vascular and glomerular diseases are 
not common causes of AKI.  
Risk factors  
AKI mostly occurs in connection with another medical condition or event. 
Advanced age is a major risk factor for many forms of AKI.76 Clinical conditions that 
increase the risk of AKI include preexisting renal insufficiency (e.g., GFR of less than 60 
mL/min/1.73 m2), intravascular volume depletion, diabetes, congestive heart failure, 
peripheral artery disease, high blood pressure, liver disease, atheroembolism, and 
sepsis.65;77 Treatment-related factors that increase the risk of AKI include cardiovascular 
surgery, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme 
inhibitors/angiotensin receptor blockers (ACE-Is/ARBs), aminoglycosides, radio-contrast 
agents, and nephrotoxic chemotherapeutic agents.65;78  
Adverse outcomes 
AKI is associated with an increased risk of premature death. The reported 
mortality rates for AKI vary greatly depending on the precipitating factors, ranging from 
approximately 7% among patients with community-acquired AKI79 to more than 80% 
among patients with postoperative AKI.80;81 Age is a major risk factor for in-hospital 
death in both young and elderly patients. In the 2009 Annual Data Report, the USRDS 
analyzed in-hospital mortality in patients with AKI hospitalizations 2006-2007 using a 
large employer group health plan dataset and the Medicare 5% sample dataset (Table 
8.d)82 In commercially insured patients, the adjusted odds ratio of in-hospital death 
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during an AKI hospitalization is 1.48 (95% confidence interval [CI]: 1.18-1.87) in 
patients aged 55-64 years compared with those aged 20-44 years. In Medicare fee-for-
service patients, the adjusted odds ratio is 1.41 (95% CI 1.30-1.52) in patients aged 80 
years and older compared with those aged 66-70 years.  
AKI is usually considered to be reversible without long-term effect on kidney 
function after the underlying cause has been treated. However, in some cases, CKD or 
end-stage renal disease (ESRD) may develop. Several studies have shown that patients 
who survived AKI are at an increased risk for CKD and/or ESRD.83-86 Patients with pre-
existing CKD are likely to progress in CKD stage after an AKI episode. In the 2012 
Annual Data Report, the USRDS compared CKD status before and after an AKI 
hospitalization in Medicare fee-for-service enrollees with an AKI hospitalization in 2010 
(Figure 6.21, p.106).4 In this analysis, Medicare claims with qualifying International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis 
codes for CKD were assembled in the 1 year prior and 1 year following the AKI 
admission date. CKD stage was defined through the ICD-9-CM diagnosis code 585.X. A 
significant change in CKD status was observed after an AKI hospitalization. Of patients 
with stages 1-2 CKD before the hospitalization, 42.8% were reclassified as having stages 
3-5 CKD within 1 year after discharge. Of patients with stages 3-5 CKD at baseline, 
12.6% were later registered in the ESRD program.  
Diagnosis 
AKI can be verified through a spot check for protein or albumin in the urine. A 
more sensitive test for protein or albumin in the urine involves laboratory measurement 
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and calculation of the protein-to-creatinine or albumin-to-creatinine ratio (ACR). Recent 
guidelines recommend estimating GFR using prediction equations based on serum 
creatinine, age, sex, race, and body size. The two most commonly used equations in 
adults include the Cockcroft-Gault equation87 and the simplified Modification of Diet in 
Renal Disease (MDRD) Study equation.88 
Although estimated GFR is used to clinically assess the degree of kidney 
impairment and to follow the disease progression, it provides no information on the cause 
of AKI. The cause of AKI is usually determined through urinalysis, measurement of 
urinary protein excretion. Sometimes, imaging tests such as ultrasound and computerized 
tomography and/or kidney biopsy are necessary to determine the exact cause of the 
kidney failure.65 
2.2.2.2 Chronic Kidney Disease 
Definition 
CKD is characterized by a progressive course with ongoing loss of kidney 
function. According to the National Kidney Foundation (NKF) Kidney Disease Outcome 
Quality Initiative (K/DOQI) Clinical Practice Guidelines,1 the criteria for diagnosis of 
CKD are either kidney damage or GFR less than 60 mL/min/1.73 m2 body surface area, 
with or without kidney damage, for 3 or more months. Kidney damage is defined by 
structural or functional abnormalities of the kidney, with or without decreased GFR, 
manifest by either pathological abnormalities or markers of kidney damage, including 
abnormalities in the composition of the blood or urine, or abnormalities in imaging tests. 
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Staging/Classification  
According to the K/DOQI guidelines, CKD is classified in five stages, based on 
estimated GFR and irrespective of diagnosis (Table 2-3). 
 
Table 2-3 NKF classification of chronic kidney disease 
Stage Description GFR (mL/min/1.73 m2) 
1 Kidney damage with normal or better GFR ≥ 90 
2 Kidney damage with mild decrease in GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure < 15 (or dialysis) 
 (Note: adapted from Table 33, p. S65)1 
Epidemiology 
CKD is a worldwide public health problem. In the U.S., the prevalence of CKD 
increased from 10% based on NHANES 1988-1994 to 13% based on NHANES 1999-
2004. Approximately 26 million adults currently have CKD.3 Data from NHANES 1999-
2004 also demonstrated that prevalence of CKD stages was 1.8%, 3.2%, 7.7%, and 
0.35% for stage 1 to stage 4, respectively.3 In 2012, the USRDS reported that the 
prevalence of recognized CKD among Medicare patients aged 65 years or older increased 
from 2.7% in 2000 to 9.2% in 2010 (Figure 2.2, p.55)4 Using a Medicare claims-based 
definition, the USRDS reported that the incidence of recognized CKD among Medicare 
patients aged 65 years or older increased almost 4 times during 1995-2008, from 1.2% in 
1995 to 4.3% in 2008 (Figure 2.4, p.57).89 
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CKD is also common in adult cancer patients.9 A recent study of 4,684 adults 
(mean age 58 years) undergoing treatment for solid tumors in 15 French centers (the 
Renal Insufficiency and Anticancer Medications [IRMA] study) found that 50% to 60% 
had creatinine clearance below 90 mL/min/1.73 m2, which defines stage 2 CKD 
according to the K/DOQI guidelines.9 However, this study did not investigate whether 
this high prevalence of reduced GFR related to the cancer itself or to cancer treatment. In 
2012, the USRDS reported that the prevalence of recognized CKD in Medicare cancer 
patients age 65 years or older was 15.8% (Table 2a, p.54).4 These apparently much 
different CKD prevalence estimates may be explained by the different definitions of 
(creatinine clearance in the IRMA study, Medicare claims-based definition in the USRDS 
study) and timing of evaluation (during treatment in the IRMA study, pre-specified 
calendar year in the USRDS study). The incidence of CKD associated with cancer 
treatment is discussed in Section 2.2.4.2.  
Causes 
The exact cause of CKD is not always identified. However, any condition or 
disease that damages blood vessels or other structures in the kidneys may cause CKD. 
The two leading causes of CKD are diabetes and hypertension, which account for up to 
two-thirds of all CKD cases.1 High blood sugar levels caused by diabetes could damage 
blood vessels in the kidneys. If the blood sugar level remains high, this damage gradually 
reduces kidney function. Uncontrolled high blood pressure is a leading cause of heart 
attacks, strokes, and CKD. Also, blood pressure often rises with CKD. High blood 
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pressure may further damage kidney function when another medical condition initially 
caused the disease.     
Other conditions that can damage the kidneys and cause CKD include 1) kidney 
diseases and infections, such as polycystic kidney disease, pyelonephritis, and 
glomerulonephritis; 2) obstructions caused by renal artery stenosis, kidney stones, 
enlarged prostate gland in men, and cancers of bladder and kidney; 3) lupus and other 
diseases affecting the body’s immune system; and 4) long-term use of medicines that can 
damage the kidney, such as NSAIDs and certain antibiotics.     
Risk factors 
The NKF defined risk factors for susceptibility to and initiation and progression 
of CKD (Table 39-40).1 Clinical factors for susceptibility to and initiation of CKD 
include diabetes, hypertension, autoimmune diseases, systemic infections, urinary tract 
infections, urinary stones, lower urinary tract obstruction, neoplasia, family history of 
CKD, recovery from AKI, reduction in kidney mass, exposure to certain drugs, and low 
birth weight. Sociodemographic factors for susceptibility to and initiation of CKD 
include older age, US ethnic minority status, exposure to certain chemical and 
environmental conditions, and low income/education. The risk factors for progression of 
CKD include higher level of proteinuria, higher blood pressure level, poor glycemic 
control in diabetes, and smoking.  
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Adverse outcomes 
Cardiovascular disease, premature death, and kidney failure are the three primary 
adverse consequences of CKD.1 Studies have shown that patients with CKD are 20 to 50 
times more likely than non-CKD patients to die than to survive to more advanced CKD 
stages or ESRD.5-7 In a study using a large health plan dataset, Go et al showed that lower 
levels of GFR are associated with higher incidence of cardiovascular events.5 In another 
study using the Medicare claims data,7 Collins et al demonstrated that patients with CKD 
without documented cardiovascular disease were 60% more likely than patients without 
CKD to acquire cardiovascular diagnosis codes and services over a 1-year period. In a 
recent meta-analysis including 105,872 individuals from 14 studies with urine ACR 
measurements and 1,128,310 individuals from 7 studies with urine protein dipstick 
measurements, Matsushita et al demonstrated that estimated GFR and albuminuria were 
both associated with risk of all-cause mortality and cardiovascular mortality.8 
Diagnosis 
CKD can be diagnosed by chronically reduced GFR and persistent proteinuria. In 
addition, renal hematuria, pyuria, glycosuria, and other kidney abnormalities defined by 
radiologic or pathologic studies are used to diagnose CKD. 
 
2.2.3 Pathogenesis of Nephrotoxicity of Selected Chemotherapeutic Agents  
Chemotherapeutic agents cover a wide range of drugs that target different types of 
cancers. Of these drugs, several are inherently nephrotoxic, including cisplatin, 
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carboplatin, ifosfamide, and high-dose methotrexate (≥ 1 g/m2), while others may be 
nephrotoxic based on preliminary understanding of the mechanism. Only 
chemotherapeutic agents commonly given in the adjuvant setting for the treatment of 
breast cancer and known as nephrotoxic or potentially nephrotoxic are discussed below, 
including methotrexate, cyclophosphamide, and doxorubicin. 
2.2.3.1 Methotrexate 
Methotrexate (MTX) is an anti-folate drug that inhibits the metabolism of folic 
acid. MTX and its metabolites are eliminated predominantly by the kidneys, through 
glomerular filtration and tubular secretion. After intravenous administration, 70% to 
100% of the drug appears in the urine in the first 24 hours.62 
Several mechanisms have been proposed for MTX-induced nephrotoxicity: 
precipitation of MTX and its metabolites in the distal tubules producing obstructive 
uropathy and tubular necrosis,90-92 direct toxic effect of MTX on the renal tubules,93 and 
possibly, alteration of GFR.94 Among these mechanisms, tubular precipitation is the most 
commonly accepted mechanism. 
2.2.3.2 Cyclophosphamide 
Cyclophosphamide (CP) is one of the commonly used and highly effective 
cytotoxic drugs of the alkylating agents. CP is initially oxidized to active and inactive 
metabolites that are excreted by the kidneys.95 The 24-hour urinary excretion of intact 
parent compound is 1% to 14%.  
 23 
 
CP has been known for its association with urotoxic side effects, such as 
hemorrhagic cystitis, but not with tubular injury.96 The pathogenic mechanisms of CP-
induced nephrotoxicity remain unknown, but earlier and recent animal studies have 
shown that oxidative stress is thought to play a role in the pathogenesis of CP-induced 
renal damage.97-102 
2.2.3.3 Doxorubicin  
Doxorubicin (DOX) is an anthracrycline antibiotic agent. Following systemic 
administration, it is rapidly and extensively metabolized by the liver to doxorubicinol. 
The main route of excretion is through bile, while urinary elimination accounts for 
approximately one-sixth of total excretion.103 
Anthracycline agents are mostly known for their cardiotoxicity.12-14;16;17 The 
molecular mechanism responsible for the pathogenesis of DOX-induced renal injury is 
not clearly defined. Animal studies have suggested that the possible mechanisms of 
DOX-induced renal toxicity may be alterations of the permeability of the glomerular 
capillary wall and glomerular atrophy104;105 or the consequence of free radical formation, 
iron-dependent oxidative damage of biological macromolecules, and membrane lipid 
peroxidation.105-108 
2.2.4 Current Literature on Chemotherapy-Induced Nephrotoxicity 
2.2.4.1 Acute Kidney Disease 
AKI has been reported following administration of high dose MTX in case 
reports, cohort studies, and clinical trials. Ahmad et al reported that a 47-year-old man 
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with chondrosarcoma of the pelvis with pulmonary metastasis presented sustained AKI 
within 2 days after starting the second course of high dose MTX therapy and died 12 days 
after receiving MTX.44 Renal histological studies showed severe tubulointerstitial 
damage consistent with MTX toxicity. Another study by Jaffe and Traggis reported that 6 
of 41 patients who received high-dose methotrexate for osteogenic sarcoma developed 
nephrotoxicity and two of these episodes were fatal.45 In a review of 20 published clinical 
trials of 3,887 patients with osteosarcoma who received high-dose MTX, approximately 
1.8% developed nephrotoxicity that was either Grade ≥ 2 (World Health Organization 
criteria) or significant enough to be reported at some time during treatment.46 
AKI has also been reported following administration of intermediate doses of 
MTX.47;48 Stark et al reported that four men aged 42-67 years developed renal failure in 
5-7 days after receiving 200 mg/m2 MTX for high-grade lymphoma despite normal serum 
creatinine prior to chemotherapy.48 
Low-dose MTX treatment has not been believed to have significant renal effects. 
However, studies have shown that nephrotoxicity can occur at low MTX doses. In a study 
of 13 patients with classic or definite rheumatoid arthritis receiving low-dose MTX 
treatment with 15 mg oral MTX weekly, Seideman et al found a significant decrease in 
GFR (P < 0.05) in all patients after 4-8 weeks of treatment.49 In another study of 13 
patients with advanced carcinomas, Condit et al reported that MTX in doses of 0.5-3 
mg/kg resulted in elevated blood urea nitrogen (BUN) and creatinine in 5 patients. Three 
of these patients had persistent azotemia at the time of death. Post-mortem examination 
of the kidneys showed extensive necrosis of the tubular epithelial cells.50 
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Although earlier and recent animal studies have shown that doxorubicin caused 
significantly increased levels of kidney markers including BUN, serum creatinine, urine 
protein, and urine albumin,107;109;110 and damage of glomerular structure,107;109 only one 
case report links anthracyclines with renal failure in humans.111 The renal biopsy in this 
patient demonstrated pathologic lesions resembling those in rats treated with the related 
anthracycline, daunorubicin. In the absence of other case reports linking anthracyclines 
with renal failure, the nephrotoxic potential of doxorubicin in humans seems low.  
Similar to doxorubicin, cyclophosphamide causes renal toxic reactions in 
experimental animal models,97-102 but there have been no reports of this problem in 
humans.  
To date, two population-based studies address incidence of AKI in adult breast 
cancer patients.112;113 In a recent Danish population-based cohort study of 46,880 incident 
cancer patients of all ages diagnosed 1999-2006,112 Christiansen et al examined the 
incidence rate and cumulative incidence of AKI at 1 year and 5 years of follow-up and 
found that the 1-year risk of AKI was highest among patients with kidney cancer, liver 
cancer, or multiple myeloma and lowest among patients with testis cancer, breast cancer, 
or malignant melanoma. Of 3,938 breast cancer patients with a baseline creatinine 
measurement, the 1-year incidence rate of AKI, defined as > 50% increase in serum 
creatinine compared with baseline level, was 48 per 1,000 person-years (95% CI 41-56 
per 1,000 person-years) and the 1-year risk of AKI was 4.5% (95% CI 3.9%-5.2%). 
Langeberg et al conducted a retrospective cohort study using a large national commercial 
claims database.113 Among 13,150 women diagnosed with breast cancer 2000-2007, aged 
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18-64 years at diagnosis, with no history of renal insufficiency, the cumulative incidence 
of AKI, defined using at least one inpatient or two outpatient claims with ICD-9-CM 
code 584.XX or 586.XX, within a year after cancer diagnosis was 0.3% in all patients 
and 1.0% in patients who received nephrotoxic chemotherapy.  
Most studies in the literature so far focus on reporting incidence of AKI. Few 
studies have evaluated the occurrence of AKI in elderly cancer patients and the 
association between chemotherapeutic agents and risk of AKI. 
2.2.4.2 Chronic Kidney Disease 
Few studies in the literature have evaluated the incidence of CKD and the 
association between chemotherapy and risk of development of CKD in elderly cancer 
patients. Current understanding of the incidence of CKD and the association between 
cytotoxic chemotherapeutic agents and risk of CKD in cancer patients comes mainly 
from studies in childhood cancer survivors.37-42 Data from the UK Renal Registry Report 
indicated that 1.9% of cases of established renal failure in children were owing to 
malignancy (whereas malignancy occurs in only about 0.17% of children) and 0.8% was 
caused by drug nephrotoxicity.40 A report from the Childhood Cancer Survivor Study 
(CCSS) in North America showed that severe chronic renal disease (grade 3 to 4 World 
Health Organization criteria) was uncommon, being present in only 0.8% of long-term 
survivors aged 18 years or older who had completed at least 5 years of treatment. 
However, this incidence was significantly more common than in their siblings (0.2%, 
relative risk 8.1, 95% CI 2.9-23.1).38 Another CCSS study of over 10,000 survivors of 
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childhood cancer reported that 0.5% had developed renal failure or required dialysis, with 
a relative risk to siblings of 8.9 (95% CI: 2.2-36.6).41 
2.3 Clinical Practice Guidelines for Surveillance and Management of 
Nephrotoxicity  
For childhood cancer survivors, the Children’s Oncology Group Long-Term 
Follow-Up Guidelines (COG LTFU Guidelines) for Survivors of Childhood, Adolescent, 
and Young Adult Cancers were developed through the collaborative effects of the 
Children’s Oncology Group Late Effects Committee, Nursing Discipline, and Patient 
Advocacy Committee.114 The COG LTFU Guidelines are risk-based, exposure-related 
clinical practice guidelines designed for asymptomatic survivors beginning with routine 
medical follow-up 2 or more years after completion of cancer treatment. The guideline 
recommends that all asymptomatic survivors undergo baseline screening including blood 
pressure measurement, serum electrolytes including Ca, Mg, and P, BUN/creatinine, and 
urinalysis and annual follow-up exams including blood pressure measurement and 
urinalysis. Referral to a nephrologist should be prompted in the presence of progressive 
renal insufficiency, proteinuria, or hypertension.  
For cancer survivors diagnosed and treated as adults, there are no clear guidelines 
for the optimal intervals and total duration of kidney function monitoring. The currently 
available clinical guidelines are designed for each specific cancer type and intended to 
provide guidance for cancer treatment and follow-up of the survivor’s primary disease. 
The National Comprehensive Cancer Network (NCCN) has developed more than 100 
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clinical practice guidelines for about 95% of the clinical situations presented by cancer 
patients.51 Although the guidelines for chemotherapy treatment recommend that renal 
function should be assessed prior to each cycle for potential dose modification for several 
nephrotoxic agents,51 there is no survivorship guideline for monitoring kidney function in 
cancer survivors. The NCCN guidelines for breast cancer follow-up include a physical 
exam every 4-6 month for 5 years, then every 12 months, and a mammogram every 12 
months (and 6-12 month post-radiation therapy if breast conserved). 
The American Society of Clinical Oncology (ASCO) guidelines for breast cancer 
follow-up and management115 include regular physical examinations (every 3-6 months 
for the first 3 years after the first treatment, every 6-12 months for years 4 and 5, and 
every year thereafter), mammograms (1 year after the first mammogram that led to 
diagnosis, but no earlier than 6 months after radiation therapy, every 6-12 months 
thereafter), breast self-examination (monthly), and pelvic examination. The following 
tests are not currently recommended by ASCO for regular follow-up care because they 
have not been shown to lengthen the life of breast cancer patients: complete blood count, 
liver enzymes, chest x-ray, bone scan, liver ultrasound, computed tomography, 
fluorodeoxyglucose-positron-emission tomography scan, breast magnetic resonance 
imaging test, and breast cancer tumor markers. 
In 2007, the ASCO Cancer Survivorship Expert Panel published extensively 
reviewed evidence of cardiac and pulmonary late effects. The intent of this rigorous 
review was to establish an evidence-based clinical guideline for survivorship care. After 
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the review, the panel concluded that the evidence was not sufficient to support an 
evidence-based clinical practice guideline for survivorship care.116 
The 2006 Kidney Disease Improving Global Outcomes (KDIGO) Controversies 
Conference on CKD was convened to discuss six major topics regarding CKD 
classification, CKD screening and surveillance, public policy for CKD, cardiovascular 
disease and its risk factors as risk factors for development and progression of CKD, 
association of CKD with chronic infections, and association of CKD with cancer.2 The 
meeting proposed three recommendations for cancer patients: “1) all cancer patients 
should be screened for CKD at diagnosis, at initiation, and change of cancer therapy. 
Tests for CKD should include a urinalysis (for hematuria and proteinuria) and a measure 
of kidney function (serum creatinine to estimate GFR); 2) kidney sparing interventions 
should be utilized in patients with kidney and uroepithelial cancers; 3) screening for CKD 
is recommended in subjects cured of cancer who are at risk for CKD, because of the type 
of cancer, its complications, its treatment, or other risk factors for CKD not related to 
cancer.” 
2.4 Significance of Current Study 
Cancer is a disease that mainly affects the elderly. Approximately 60% of patients 
diagnosed with cancer are aged ≥ 65 years.10;11 As the U.S. population continues to age, 
the number of newly diagnosed elderly cancer patients will expand. Since renal function 
is expected to deteriorate with increasing age,43 elderly cancer patients who receive 
chemotherapy treatment have an increased risk of AKI. Although AKI induced by 
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chemotherapeutic agents has been extensively investigated, most studies have been 
limited to case reports, small cohort studies, or clinical trials.44-50 Since elderly cancer 
patients are usually underrepresented in clinical trials, little information is available on 
the occurrence of AKI as an adverse outcome of chemotherapy treatment in elderly 
cancer patients. To date, no population-based study has estimated the incidence of AKI 
and the magnitude of association between nephrotoxic chemotherapeutic agents and the 
risk of AKI in elderly cancer patients. 
Most AKI episodes caused by cancer treatment are reversible. However, initial 
acute toxicity caused by some cytotoxic chemotherapy agents can progress to CKD with 
the development of chronic tubulointerstitial nephritis, papillary necrosis, or prolonged 
proteinuria.117 With the development of effective cancer screening and treatment, many 
patients with cancers are cured and live for extended periods after the completion of 
treatment, and may have an elevated risk for CKD as a late effect of chemotherapy 
treatment. Studies of CKD as a late effect of chemotherapy have mainly focused on child 
and adolescent cancer survivors.37-42 The clinical practice guidelines for survivorship care 
have been developed for surveillance and management of nephrotoxicity for 
asymptomatic pediatric cancer survivors. However, little attention has been given to 
CKD as a late effect of chemotherapeutic agents in adult cancer survivors and there is 
currently no clinical practice guideline for kidney function monitoring in adult cancer 
survivors. Patterns of clinical practice regarding renal function monitoring in elderly 
cancer patients after completion of cancer treatment, especially patients treated with 
nephrotoxic chemotherapeutic agents, are unknown. 
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I conducted three retrospective cohort studies using the linked SEER-Medicare 
data to investigate (1) the association between adjuvant chemotherapy and risk of AKI 
among elderly women with breast cancer, (2) the association between adjuvant 
chemotherapy and risk of CKD among elderly women with breast cancer, and (3) clinical 
practice patterns of kidney function monitoring among elderly breast cancer patients after 
completion of treatment by adjuvant chemotherapy status.  
I chose breast cancer for the proposed body of work based on the following 
considerations. First, breast cancer is a major public health issue. In the U.S., breast 
cancer is the most frequently diagnosed cancer and the second leading cause of cancer 
death in women. An estimated 207,090 women were diagnosed with breast cancer (28% 
of all female cancer cases and 13.5% of all incident cancers) and 39,840 died of breast 
cancer (15% of all female cancer deaths and 7% of all cancer deaths) in 2010.52 
Second, breast cancer has a high survival rate. Approximately 89% of breast 
cancer patients survive for more than 5 years, and the 5-year relative survival is higher 
among women with a less advanced stage at diagnosis (98% for localized disease) and 
among women diagnosed with breast cancer at age 40 or older (90%).118 With advances 
in early detection and effective treatment of cancer, the number of cancer survivors 
increased in the U.S. from approximately 3 million in 1971 to 12 million in 2007.119 
Breast cancer survivors represented the largest proportion of female cancer survivors 
(41%) and of all cancer survivors (22%) on January 1, 2008.53 
Finally, the evidence of nephrotoxicity for chemotherapeutic agents commonly 
used in the treatment of breast cancer is lacking. Though nephrotoxicity caused by high-
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dose MTX has been extensively investigated, low-dose MTX is usually used in 
conjunction with cyclophosphamide and 5-FU (CMF regimen) in treating breast cancer 
patients in the adjuvant setting. Whether low-dose MTX could cause nephrotoxicity 
remains unknown. In addition, recent animal studies suggested that doxorubincin, another 
widely used anthrocycline agent in breast cancer treatment, may induce renal damage 
through oxidative stress. No population-based studies have evaluated nephrotoxcity 
induced by doxorubincin. 
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Chapter 3 Methods 
3.1 Data source 
This study used a database developed by the U.S. National Cancer Institute (NCI) 
and the Center for Medicare & Medicaid Services (CMS). The NCI-sponsored 
Surveillance, Epidemiology, and End Results (SEER) program includes population-based 
tumor registries that routinely collect information on all newly diagnosed cancer 
(incident) cases in SEER areas since January 1, 1973. In 1991, when the SEER data were 
initially linked to Medicare, the SEER areas included the states of Connecticut, Hawaii, 
Iowa, New Mexico, and Utah, and the metropolitan areas of Detroit, San Francisco-
Oakland, Atlanta, and Seattle-Puget Sound, representing approximately 10% of the U.S. 
population. In 1992, two registries from Los Angeles County and the San Jose-Monterey 
areas became available, increasing the SEER representation to approximately 14% of the 
U.S. population. In 2000, four registries from Kentucky, Louisiana, New Jersey, and the 
remainder of California were added, increasing the SEER area coverage to approximately 
25% of the U.S. population. The SEER registries collect information about each incident 
cancer case from multiple reporting sources such as hospitals, outpatient clinics, 
laboratories, private medical practitioners, nursing/convalescent homes/hospices, autopsy 
reports, and death certificates.119 The information collected includes demographic 
characteristics such as age, sex, race, and marital status; cancer-related characteristics 
such as tumor location, size, histology, American Joint Committee on Cancer (AJCC) 
stage, axillary node status, grade, and estrogen receptor status; and type of treatment 
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provided within 4 months of diagnosis, follow-up of vital status, and cause of death, if 
applicable. 
The CMS-sponsored Medicare program is the primary health insurer for 97% of 
the U.S. population aged ≥ 65 years. All Medicare beneficiaries receive Part A (hospital 
insurance) coverage for inpatient care, skilled nursing facilities, home health, and hospice 
care. Ninety-five percent of beneficiaries also subscribe to Part B (medical insurance) 
coverage for physician services, outpatient care, durable medical equipment, and in some 
cases home health.119  
The linkage of SEER and Medicare data is conducted by NCI and CMS based on 
an algorithm involving a match of Social Security number, name, sex, and date of 
birth.120 The SEER data available as part of SEER-Medicare files are in the Patient 
Entitlement and Diagnosis Summary File (PEDSF), which includes all SEER data, 
Medicare eligibility, Medicare demographic variables, reason for Medicare entitlement, 
and health maintenance organization (HMO) enrollment for each individual in the SEER 
data who has been matched with Medicare enrollment records. The Medicare data 
available as part of SEER-Medicare files are claims from Medicare Provider Analysis 
and Review (MedPAR) short-stay hospital, MedPAR skilled nursing facility, home health 
agency, hospital outpatient, physician, and hospice providers. All Medicare files include 
information on demographics, date(s) of service, diagnostic codes, and procedure codes, 
in addition to the amounts of charges and reimbursement. The SEER-Medicare 2010 
linkage data include cancer cases reported to SEER from 1973 through 2007 and all 
associated Medicare claims from 1991 (1998 for incident cases 2003 to 2005 and 2000 
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for incident cases 2006 to 2007) to 2009. Medicare hospitalization claims are available 
back to 1986. 
3.2 Study Population, Inclusion and Exclusion Criteria 
The study population includes women who were diagnosed with unilateral breast 
cancer from 1992 to 2007, surgically treated, aged 66-89 years at the time of diagnosis, 
and continuously enrolled in Medicare both Part A and Part B during the month of 
diagnosis and the 12 months before the month of diagnosis.  
The study population excludes women who participated in an HMO during the 
month of diagnosis or the 12 months before diagnosis because Medicare claims data are 
often incomplete for these patients; women who were diagnosed with AJCC stage 0 or 
stage IV disease because adjuvant chemotherapy treatment is the focus of the study; 
women who had liver disease because liver disease affects chemotherapy use; women 
who had claims evidence of AKI, CKD, or ESRD before diagnosis of primary breast 
cancer because AKI and CKD are the two main outcomes under study; and women who 
had a prior breast cancer or other cancer, had claims evidence of cancer in situ or 
metastasis, had claims evidence of cancer treatment including radiotherapy, 
chemotherapy, breast-conserving surgery, or mastectomy, to ensure that breast cancer is 
the first primary cancer and that patients are treatment naive at the time of study.  
3.3 Study Design 
The study used a 1:1 individually matched, retrospective cohort design to 
compare the risk of AKI and CKD and to evaluate kidney function monitoring between 
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chemotherapy-treated and untreated breast cancer patients. Breast cancer patients with 
advanced stages or hormone receptor negative tumors were more likely to receive 
chemotherapy. Other non-tumor related factors may also affect decisions about 
chemotherapy treatment in elderly patients, including age, race, and presence of 
comorbid conditions, which are also risk factors for AKI and CKD.1;65;76;77 Matching may 
reduce treatment selection bias because of factors that may have influenced physicians or 
patients to choose chemotherapy and may be related to the outcomes.121  
Because time from the first cancer-directed surgery to initiation of adjuvant 
chemotherapy varies among patients treated with chemotherapy, and the underlying 
hazard of AKI and CKD may not be constant after surgery, time-dependent matching at 
the day of chemotherapy initiation was used. For all patients who met the study inclusion 
and exclusion criteria, initiation of adjuvant chemotherapy was identified within 6 
months (183 days) after the date of first surgery. Cox proportional hazards modeling was 
used to estimate the probability of initiating adjuvant chemotherapy at each day of 
follow-up for each patient. At each time point when one or more patients initiated 
adjuvant chemotherapy, patients who received chemotherapy on that day were 
individually matched using the Greedy Match algorithm122 with patients who had the 
same or similar probability of receiving chemotherapy but had not yet initiated 
chemotherapy on that day. Detailed information on time-dependent matching is described 
in Section 3.5.1.  
The assembled matched cohorts were used in the analyses for all three objectives 
with different follow-up start and end dates defined for each study objective. For 
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objectives 1 and 2, follow-up began on the chemotherapy initiation date of the matched 
treated patient for each matched pair. For objective 1, follow-up ended at AKI 
occurrence, CKD diagnosis, death, change in Medicare both Part A and Part B 
enrollment, participation in an HMO, development of second non-breast cancer, or 6 
months after the follow-up start date, whichever came the earliest. For patients in the 
matched untreated cohort, follow-up time was also censored at initiation of chemotherapy 
after first surgery. For objective 2, follow-up time was not censored at AKI occurrence 
and the follow-up end date was extended to December 31, 2009, if no other censoring 
events occurred.  
Because objective 3 was to compare utilization of kidney function monitoring 
tests between chemotherapy-treated and untreated patients after completion of treatment, 
the period of time when patients were under chemotherapy treatment should not be 
considered. Therefore, for patients who were treated with chemotherapy, the follow-up 
period began on the day following completion of the adjuvant chemotherapy course. 
Since the chemotherapy course duration varied, time from the matching date to follow-up 
start date was different among treated patients. To ensure that similar time elapsed for 
patients in the matched untreated cohort, the follow-up start date for the untreated cohort 
was the date of matching plus the median course duration (112 days). Thus, on average, 
an equal time period elapsed after the matching date between the two cohorts. Follow-up 
ended at diagnosis of CKD, development of a second non-breast primary cancer, death, 
change in Medicare both Part A or Part B enrollment, participation in an HMO, or 
December 31, 2009, whichever occurred the earliest. For patients who received 
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chemotherapy for treatment of recurrence or non-breast primary cancer, the duration of 
the subsequent chemotherapy course(s) was excluded from the follow-up period because 
kidney function was likely monitored during the treatment. Because lab tests were likely 
performed a few days before or on the day of chemotherapy treatment to examine patient 
health status, one week before the initiation of a subsequent chemotherapy course was 
also excluded to avoid counting pre-chemo kidney function testing as kidney function 
monitoring after treatment. Comorbid conditions were re-evaluated for all patients during 
the 12 months before follow-up began to control for residual confounding in the analysis 
stage. The outcome of interest was the total number of laboratory tests assessing renal 
function for each type. If the renal-related laboratory test occurred on the same day as 
CKD diagnosis, the laboratory test was not considered because it may be the diagnostic 
test for CKD, not screening for CKD.  
3.4 Definitions of Study Variables 
3.4.1 Chemotherapy 
Chemotherapy exposure was identified using a constellation of International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis 
codes and procedure codes, Current Procedure and Terminology (CPT) codes, Healthcare 
Common Procedure Coding System (HCPCS) codes, revenue codes, and Diagnosis-
Related Groups (DRG) codes in Medicare inpatient, outpatient, and physician claims. 
Hospital claims contain ICD-9-CM diagnosis codes, ICD-9-CM procedures codes, and 
DRG codes that were used to identify chemotherapy administration, but not specific 
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agents. Chemotherapeutic agents were identified through HCPCS codes reported on 
outpatient and physician claims. Chemotherapy administration in an outpatient setting 
was identified through ICD-9-CM diagnosis and procedure codes and revenue codes 
reported on outpatient claims, and through ICD-9-CM diagnosis codes and CPT codes 
reported on physician claims. Codes used to identify receipt of chemotherapy are detailed 
in Table A.1 in Appendix A. 
Three chemotherapy regimens were studied: anthracycline-based, CMF, and 
taxane-based. These regimens were defined by the following hierarchy order: 
anthracyclines->CMF->taxane. Anthracycline-based chemotherapy was defined if 
patients received doxorubicin or eprirubicin whether or not other agents were also given. 
A CMF regimen was defined if patients received cyclophosphamide, methotrexate, and 
5-fluorouracil in the absence of doxorubicin or eprirubicin. Taxane-based chemotherapy 
was defined if patients received docetaxel or paclitaxel in the absence of anthracyclines 
and CMF. Using this hierarchy order, three major types of chemotherapy were defined 
mutually exclusively because patients treated with an anthracycline-based regimen could 
have also received cyclophosphamide, 5-fluorouracil, or a taxane in addition to an 
anthracycline. Further, use of non-anthracycline-containing taxane-based chemotherapy 
has rapidly increased after 2005 due to the concern about cardiotoxicity associated with 
anthracycline-based chemotherapy.123 Patients who received none of the three regimens 
were grouped into “other” category. Codes used to define specific chemotherapy agents 
in these regimens are presented in Tables A.2 in Appendix A. 
Patients were identified as having received chemotherapy if they had a claim 
 40 
 
carrying a general chemotherapy procedure code, a diagnosis code for chemotherapy 
administration, or a HCPCS code for a specific agent. For inpatient claims for 
chemotherapy, chemotherapy date was defined as date of admission. For outpatient and 
physician claims, chemotherapy date was defined as date of service. 
Chemotherapy course was defined from the first chemotherapy claim within the 
study period (12-month baseline period before diagnosis plus the follow-up period after 
diagnosis) until the last chemotherapy claim with a less than 60-day gap between two 
consecutive claims based on the method described in a previous publication124 with slight 
modification. If a chemotherapy claim occurred 60 days or more after the date of service 
of the prior chemotherapy claim, that was considered the first claim of the next 
chemotherapy course. Adjuvant chemotherapy was defined as chemotherapy initiation 
within 6 months following the first cancer-directed surgery. 
Use of Medicare claims data to identify patients receiving chemotherapy was 
anticipated to have a high level of accuracy and completeness because chemotherapy is 
covered by Medicare and because of the nature of chemotherapy treatment (expensive, 
lengthy, and more likely administered in an outpatient setting).126 The facility/provider 
receives reimbursement for both drug costs and drug administration fees, and is therefore 
motivated to report accurately.  
3.4.2 Acute Kidney Injury  
AKI was identified through ICD-9-CM diagnosis codes and ICD-9-CM procedure 
codes, revenue codes, and CPT codes indicating dialysis in the MedPAR short-stay 
hospital, outpatient, and physician claims. In the baseline period, patients with AKI 
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occurring in either the inpatient or the outpatient setting were identified and excluded 
from the study. In the follow-up period, AKI occurring in the inpatient setting was the 
event of interest to evaluate the association between adjuvant chemotherapy and risk of 
AKI. The date of AKI was defined as the hospital admission date for AKI. Codes used to 
identify patients with AKI are detailed in Table B1 of Appendix B. 
The accuracy of ICD-9-CM codes for identifying patients with AKI has been 
assessed by Waikar et al127 using the linked administrative and laboratory data from 
97,705 adult discharges from three Boston hospitals in 2004. They reported that ICD-9-
CM diagnosis codes for AKI (584.5-584.9) had a sensitivity of 35.4%, specificity of 
97.7%, positive predictive value (PPV) of 47.9%, and negative predictive value (NPV) of 
96.1%, and the ICD-9-CM procedure codes for dialysis had a sensitivity of 90.4%, 
specificity of 93.8%, PPV of 94.0%, and NPV of 90.0%. 
3.4.3 Chronic Kidney Disease  
CKD was identified through ICD-9-CM diagnosis codes in Medicare claims 
based on a previously published methodology that has been validated for identification of 
diabetic patients using Medicare claims.128 Patients were considered to have CKD if they 
had at least one MedPAR short-stay hospital, MedPAR skilled nursing facility or home 
health agency claim, or at least two hospital outpatient or physician/supplier claims on 
different dates within a 12-month interval carrying the ICD-9-CM diagnosis codes for 
chronic renal insufficiency, diabetic nephropathy, hypertensive nephropathy, AKI, or 
miscellaneous other renal disease. The diagnosis codes for AKI were included in 
identifying CKD only in the presence of additional claims with other qualifying diagnosis 
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codes for CKD. The earliest date of claims with the qualifying diagnosis codes was 
defined as the CKD index date. Table B.2 in Appendix B lists the ICD-9-CM diagnosis 
codes used to identify CKD.  
The method used to identify CKD patients in this study is based on a previously 
published methodology that has been validated for the identification of diabetic patients 
using Medicare claims.128 Application of the same method to identify patients with CKD 
in Medicare beneficiaries with breast cancer has not been validated. However, two 
studies have examined the validity of using similar renal-related ICD-9-CM diagnosis 
codes to identify patients with CKD stages 3-5 in two patient groups.129;130 The results 
showed similar specificity (93%), 74% to 89% PPV, 27% to 42% sensitivity, and 37% to 
78% NPV.  
Of note, CKD patients identified using the methodology described above tend to 
have clinically apparent kidney disease for which the providers submit claims for clinical 
care services. Therefore, patients identified as having CKD using the claims-based 
definition represent patients with recognized CKD from the diagnoses codes in the 
Medicare claims and are likely to be in later stages of kidney disease and not to have mild 
kidney disease.7 
3.4.4 Assessment of Kidney Function  
In this study, kidney function monitoring includes laboratory blood testing of 
serum creatinine to determine whether the kidneys are functioning normally, and urine 
testing for albumin and albumin-to-creatinine ratio (ACR) to detect whether there is early 
damage to the kidneys. These measures were identified through CPT codes in the carrier 
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and outpatient claims. For services identified in the carrier claims, date of laboratory test 
was defined as the “line first expense date.” For services identified in the outpatient 
claims, date of service was defined as the “claim from” date. Codes used to identify renal 
laboratory tests and renal imaging procedures are presented in Appendix C. 
For the tests of serum creatinine and urine albumin, only one type of laboratory 
test was counted if the claim showed more than one CPT code indicating the same type of 
laboratory test on the same service day. Urinary ACR assessment required CPT codes for 
both albumin and creatinine to be present on the claim on the same service day.  
Validation studies of renal-related laboratory tests are not available. However, 
coding of laboratory tests in Medicare was anticipated to have a high level of accuracy. 
The facility/provider receives reimbursement for performing the tests, and is therefore 
motivated to report accurately. 
3.4.5 Other Study Variables 
Risk factors and potential confounders were selected based on the literature. 
Information on patient demographics, other patient characteristics, breast cancer-related 
clinical factors, and radiation therapy following breast cancer diagnosis were abstracted 
from the SEER registry database, while information on surgery type, comorbid 
conditions, cancer in situ, other primary cancer, metastatic cancer, and radiotherapy 
during the baseline period was obtained from the Medicare claims. The various data 
elements and the definitions are listed below. 
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Demographics and other patient characteristics 
Patient demographic and other characteristics were identified in SEER registry 
data and included age defined on cancer diagnosis (66-69, 70-74, 75-79, 80-84, and 85-
89 years), race (white, black, other), year of diagnosis (1992-2007), marital status 
(married, unmarried, unknown), and SEER areas (Connecticut, Detroit, Hawaii, Iowa, 
New Mexico, Seattle, Utah, Atlanta/rural Georgia, Kentucky, Louisiana, New Jersey, 
California). 
Breast cancer-related clinical factors 
Breast cancer-related characteristics were obtained from SEER registry data and 
included AJCC stage (I, II, III), tumor grade (well-differentiated, moderately 
differentiated, poorly differentiated, unknown/missing), tumor size (< 2 cm, ≥ 2 cm, 
missing), hormone receptor status (estrogen receptor positive and/or progesterone 
receptor positive, estrogen receptor negative and progesterone receptor negative, 
unknown), histology (ductal, lobular, mixed, other), lymph node status (negative, 
positive, missing), and laterality (left, right). 
Breast cancer-related treatment 
Surgery type (breast-conserving surgery, mastectomy) was identified based on 
ICD-9-CM procedure codes and CPT codes in Medicare claims data within 4 months 
after cancer diagnosis.131 SEER registry data code the most extensive procedure 
following an established hierarchy. If a patient underwent three procedures in the 
following order: biopsy->lumpectomy->mastectomy, mastectomy was coded as the type 
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of surgery. Using this method, surgery type was defined by the most extensive surgery in 
claims data. If the surgery was performed in hospital, date of surgery was defined as the 
admission date. If the surgery was performed in an outpatient setting, date of surgery was 
defined based on the service date. Table B.5 in Appendix B presents the ICD-9-CM 
procedure codes and CPT codes for breast-conserving surgery and mastectomy.   
Radiotherapy (yes, no) for breast cancer treatment was identified in the SEER 
registry database and included beam radiation, radioactive implants, radioisotopes, or 
other radiation. Radiotherapy (yes, no) during the 12-month interval before breast cancer 
diagnosis was identified from Medicare claims carrying the following codes: CPT codes 
(77401-77499, 77520-77525, 77750-77799, G0256, G0261), ICD-9-CM procedure codes 
(92.21-92.29), revenue center codes (0330, 0333), DRG codes (409), and ICD-9-CM V 
codes (V58.0, V66.1, V67.1). 
Comorbid conditions 
Comorbid conditions were identified from Medicare claims during the 12-month 
interval before cancer diagnosis and the 12-month interval before chemotherapy initiation 
using a previously published methodology,128 and include the following conditions (yes, 
no): atherosclerotic heart disease (ASHD), cerebrovascular accidents/transient ischemic 
attack (CVA/TIA), chronic obstructive pulmonary disease (COPD), congestive heart 
failure (CHF), dysrhythmia, diabetes mellitus, gastrointestinal (GI) disorders, other 
cardiovascular diseases, peripheral vascular disease (PVD), and hypertension. Table B.3 
in Appendix B list the ICD-9-CM diagnosis codes used to identify each comorbid 
condition.  
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Cancer in situ, primary cancer, and metastatic cancer 
Cancer in situ, primary cancer, and metastatic cancer were identified from 
Medicare claims during the 12-month interval before the diagnosis of the first primary 
breast cancer using a previously published methodology.128 Table B.4 in Appendix B 
presents the ICD-9-CM diagnosis codes for these conditions.  
Second non-breast primary cancer 
Second non-breast primary cancer after the diagnosis of the first primary breast 
cancer was identified in SEER registry data. 
3.5 Statistical Analysis 
All statistical analyses were performed using SAS 9.1.3 software (SAS Institute, 
Cary, NC) unless otherwise indicated. 
3.5.1 Sequential Matching on Time-Dependent Propensity Score 
The following steps were used to perform sequential matching on time-dependent 
propensity score. First, the probability (i.e., propensity score) of initiating adjuvant 
chemotherapy on each day within 6 months (183 days) after the date of first cancer-
directed surgery was estimated using the Cox proportional hazards model.132 All patients 
who met the study inclusion and exclusion criteria were followed from the date of first 
surgery to initiation of adjuvant chemotherapy; occurrence of AKI; diagnosis of CKD, 
liver disease, or non-breast primary cancer; change of Medicare Part A or Part B 
enrollment status; participation in an HMO; death; or 6 months (183 days) after the date 
of first surgery, whichever came earliest. The following patient and tumor characteristics, 
 47 
 
which may affect the choice of chemotherapy and outcome, were included in the Cox 
model as predictors: age, race, marital status, tumor stage, tumor grade, tumor size, node 
status, estrogen/progesterone receptor status, comorbid conditions, radiation therapy, 
mastectomy status, year of diagnosis, and SEER area. 
Then, at each time point when one or more patients initiated adjuvant 
chemotherapy, patients who received chemotherapy were individually matched using the 
Greedy Match algorithm122 with patients who had the same or similar probability of 
initiating chemotherapy but had not yet initiated at that time point. Because the 
probability of initiating adjuvant chemotherapy during the 6-month period ranged from 0 
to 1, the estimated daily probability would be much smaller. Thus, the matching 
algorithm was performed 8->2 digits to improve precision. On the day a patient initiated 
chemotherapy, this patient was first matched on 8 digits of the probability to a patient 
who had not yet initiated chemotherapy. If an appropriate match could not be formed, 
then a 7-digit match on the probability was attempted. This process was continued down 
to a 2-digit match on probability for patients who remained unmatched. If a treated 
patient could not be matched to any untreated patient on 2 digits, the treated patient was 
removed from the analysis. If more than one patient initiated chemotherapy at the same 
time point, these treated patients were ordered randomly and matching took place in 
order. If more than one untreated patient could be matched to a treated patient, the 
matched untreated patient was randomly selected. Patients who were matched to treated 
patients at an earlier time point were not included for future matching unless they 
initiated adjuvant chemotherapy later. Therefore, it is possible that patients in the 
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matched treatment cohort could also appear in the matched no-treatment cohort. The 
correlation was addressed in the analysis stage using the robust variance estimation. 
Because patterns of care for breast cancer patients and recognition of AKI and CKD in 
the Medicare claims database may change over years, matching was performed by year of 
cancer diagnosis. The SAS Macro program by Parsons was used to form matched 
pairs.133 
Finally, balance in baseline characteristics between the treatment cohort and the 
matched no-treatment cohort was assessed using the standardized difference134 with the 
following equation: 
Standardized difference = |𝑃𝑡−𝑃𝑐|
�𝑃𝑡(1−𝑃𝑡)+𝑃𝑐(1−𝑃𝑐)
2
                          
where Pt and  Pc denote the proportion of a given level of a categorical baseline variable 
in the treatment and the matched no-treatment cohorts, respectively.  
A standardized difference of less than 0.1 (10%) represents a rule-of-thumb for an 
acceptable balance in covariate distribution between treated and untreated subjects.135-137 
3.5.2 Patient Baseline Characteristics 
The distributions of patient characteristics were summarized for all patients, for 
patients who did and did not receive adjuvant chemotherapy before matching, and for 
patients in each study cohort after matching. Since all patient characteristics were defined 
as categorical variables, standard descriptive statistics such as counts and percentages 
were used to summarize the distributions. The chi-square test was used to compare 
frequency distributions of baseline characteristics between chemotherapy-treated and 
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untreated cohorts before matching. Standardized difference was used to evaluate balance 
in baseline characteristics before and after matching.  
The distribution of patient characteristics was also reported for patients who 
received each of the four types of chemotherapy including anthracycline-based, CMF, 
taxane-based, and others. 
3.5.3 Objective 1 Adjuvant Chemotherapy Treatment and Risk of AKI  
Counts and proportions of patients who were admitted to hospital for AKI and 
rate of AKI during the 6-month follow-up period were summarized for treated and 
matched untreated cohorts. Mean and median follow-up time was also examined.  
The cumulative incidence of AKI during the 6-month follow-up period was 
assessed using the Kaplan-Meier method. Cumulative incidence curves were stratified by 
adjuvant chemotherapy status. Differences in the cumulative incidence curves between 
the two cohorts were evaluated using the log-rank test.   
Since baseline patient characteristics were expected to be balanced in the matched 
cohorts, a Cox proportional hazards model with adjuvant chemotherapy use as the only 
independent variable was used to estimate the hazards ratio of AKI hospitalization for 
patients who received adjuvant chemotherapy compared with those who did not. Robust 
variance estimation was used to incorporate intra-patient correlation between the 
treatment and matched no-treatment cohorts.138  
Because a matched cohort study design may not achieve the perfect balance in 
patient baseline characteristics between the treated and matched untreated cohorts as a 
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randomized clinical trial would, the association between adjuvant chemotherapy and risk 
of AKI was reexamined including all factors listed in Section 3.4.5 in the Cox model. 
The analyses were repeated by regimen type (anthracycline-based, CMF, taxane-
based, others) with the matched untreated cohort as the comparison group to evaluate the 
effect of regimen type on risk of AKI with adjustment for patient baseline characteristics. 
3.5.4 Objective 2 Adjuvant Chemotherapy Treatment and Risk of CKD 
3.5.4.1 Primary Analyses 
Counts and proportions of patients with claims evidence of incident CKD and 
incidence rate of CKD during the follow-up period were summarized by adjuvant 
chemotherapy status. Incidence rate of CKD was defined as the ratio of the number of 
patients with claims evidence of CKD diagnosis divided by the total person-years at risk. 
The cumulative incidence of recognized CKD was assessed using the Kaplan-Meier 
method. Cumulative incidence curves were stratified by adjuvant chemotherapy use. 
Differences in the cumulative incidence curves between the two cohorts were evaluated 
using the log-rank test.  
A Cox proportional hazards model with adjuvant chemotherapy as the only 
independent variable was used to evaluate the association between adjuvant 
chemotherapy and risk of CKD. A robust covariance estimator was included in the Cox 
model to account for within-pair correlation.138 The assumption of proportionality of the 
hazards was assessed graphically with a Schoenfeld residual plot to determine whether a 
horizontal line was present in the graph. As explained in Section 3.5.3, the effect of 
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adjuvant chemotherapy on risk of CKD was reexamined with all factors listed in Section 
3.4.5 included in the Cox model.  
The analyses were repeated by regimen types (anthracycline-based, CMF, taxane-
based, others) with the untreated cohort as the comparison group to evaluate the effect of 
regimen type on risk of incident CKD with adjustment for patient baseline characteristics. 
3.5.4.2 Sensitivity Analysis 
Initiation of adjuvant chemotherapy as a time-varying covariate  
All patients who met the inclusion and exclusion criteria were included in this 
analysis. Initiation of adjuvant chemotherapy within 6 months after the first surgery was 
defined as a time-varying variable. The time-varying Cox proportional hazards model 
with robust covariance estimate was used to estimate the hazards ratio of CKD for 
patients who received adjuvant chemotherapy compared with patients who did not. 
Competing risk analyses 
In the primary analyses, death was one of the censoring events for time to CKD, 
under the assumption that patients who die are subject to the same risks of CKD after 
death as those remaining under observation. By this method, the estimated relative hazard 
of CKD for patients who received adjuvant chemotherapy compared with patients who 
did not represents the risk of CKD associated with chemotherapy ignoring anything that 
happened before CKD onset. 
In reality, although chemotherapy may increase the risk of CKD, this risk for 
patients who are likely to die before they develop CKD may not be of concern. For this 
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purpose, death is a competing event with CKD. To evaluate the effect of chemotherapy 
on risk of CKD during the time interval when patients remained alive, a competing risk 
analysis was performed for patients in the matched cohorts. The estimated relative hazard 
of CKD for adjuvant chemotherapy compared with no adjuvant chemotherapy reflects the 
association between chemotherapy and risk of CKD when patients were alive. 
The cumulative incidence method was used to report the observed event 
probabilities of CKD and death. A Cox regression model was used with the Fine-Gray 
method139 to assess competing risk and adjust for all factors listed in Section 3.4.5. 
Subgroup analyses by course duration 
Associations between adjuvant chemotherapy and risk of CKD were re-examined 
for subgroups of patients who received shorter chemotherapy treatment (≤ 1 week) and 
patients who received longer treatment (> 1 week).  
3.5.5 Objective 3 Utilization of Kidney Function Monitoring Tests 
Since the follow-up start date in this study was no longer the date of initiation of 
adjuvant chemotherapy for patients in the treatment cohort and the matched date for 
patients in the no-treatment cohort, the balance in patient characteristics achieved from 
matching may not be preserved. The distributions of patient characteristics were 
reexamined. Differences in patient characteristics between the treatment and no-treatment 
cohorts were evaluated using the chi-square test.     
The cumulative percentage of patients receiving at least one laboratory test related 
to renal function during the follow-up period was assessed using the Kaplan-Meier 
 53 
 
method for patients who were and were not treated with adjuvant chemotherapy. 
Differences in assessment of renal function between the two study cohorts were tested 
using the log-rank test. In this analysis, time to the first laboratory test was the event of 
interest. Thus, follow-up also ended at the date of first laboratory test for patients whose 
kidney function was assessed.  
Following the initial comparison of time to first renal function assessment 
between patients who did and did not receive adjuvant chemotherapy, the frequency of 
renal function assessment was examined in three intervals during the follow-up period. 
The cutoffs of follow-up intervals were ≤ 1 year, > 1-≤ 2 years, and > 2-< 18 years. All 
patients who survived the previous interval were included in the analysis for the 
subsequent interval. In this analysis, the total number of tests per patient (i.e., multiple 
events) was the outcome of interest. For each interval, person-time was defined from the 
beginning of the interval to the end of the interval or the end of follow-up. The 
unadjusted rate of renal-related testing was calculated as the ratio of the total number of 
kidney function laboratory tests divided by the total person-years of follow-up and 
measured as number of tests per 1,000 patient-years. The rate ratio of renal function 
testing in chemotherapy-treated patients compared with untreated patients was estimated 
using an interval Poisson regression model with adjustment for baseline characteristics 
including patient demographics, comorbid conditions, and tumor characteristics. 
Analyses were performed for each laboratory test.   
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Chapter 4 Results 
This chapter is divided into four components. The first presents patient 
characteristics for the study cohorts before and after time-dependent matching. The 
remaining three components sequentially present the results of objectives 1, 2, and 3. 
4.1 Patient Baseline Characteristics 
A total of 175,472 women with breast cancer diagnosed between 1992 and 2007 
and aged 66 to 89 years at diagnosis were identified in SEER-Medicare linkage data. Of 
these women, 84,018 met the study inclusion and exclusion criteria. Figure 4-1 illustrates 
the process of patient selection.  
 
 
  
 55 
 
Figure 4-1 Flow diagram for selection of patients. AKI, acute kidney injury; BC, breast 
cancer; BCS, breast-conserving surgery; CKD, chronic kidney disease; FFS, fee-for-
service; MST, mastectomy 
  
Women with BC diagnosed between 
1992 and 2007 and aged 66-89 years 
at diagnosis (N=175,472) 
Medicare FFS enrollees during the 
month of diagnosis with continuous 
enrollment during the 12 months 
before diagnosis (N=122,018) 
Did not have certain health conditions 
or receive cancer-related treatment at 
baseline (N=112,003) 
Had AJCC Stages I to III tumor 
(N=93,801) 
Had first surgery within 4 months 
after BC diagnosis (N=84,716) 
Patients included for analyses 
(N=84,018) 
Had ESRD or had claims evidence of 
AKI, CKD, liver disease, cancer, 
metastases, chemotherapy, 
radiotherapy, or BCS/MST during 12 
months before cancer diagnosis 
 
Not continuously enrolled in 
Medicare FFS during baseline and 
the month of diagnosis 
148 patients had stage 0 cancer; 5,804 
had stage IV cancer, and 12,250 had 
stage unknown. 
Excluded 18,202 patients  
7,131 patients did not have surgery 
and 1,954 patients had first surgery 
after 4 months of diagnosis.  
Excluded 9,085 patients  
Received chemotherapy before the 
first surgery, or had bilateral cancer or 
laterality unspecified, or had had AKI, 
CKD, or liver disease before the first 
surgery.  
Excluded 10,015 patients  
Excluded 53,724 patients  
Excluded 698 patients  
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Of women included in the study, 14,725 (17.5%) received adjuvant 
chemotherapy. Demographic characteristics, tumor characteristics, and comorbid 
conditions differed substantially between patients who were and were not treated with 
adjuvant chemotherapy. Patients who received adjuvant chemotherapy, compared with 
patients who did not, were younger, more often black, diagnosed at later stages, more 
likely to be hormone receptor negative, more likely to undergo mastectomy, more likely 
to have diabetes at baseline, and less likely to have cardiovascular disease or other 
comorbid conditions at baseline (Table 4-1).  
Of 14,725 patients treated with adjuvant chemotherapy, 14,024 (95.2%) could be 
individually matched to untreated patients at the time of chemotherapy initiation. Of 
these patients, 3,982 (28.4%) were also present in the matched no-chemotherapy cohort. 
A total of 516 patients (3.7%) in the matched no-chemotherapy cohort also initiated 
adjuvant chemotherapy at a later time after matching, but could not be matched to an 
untreated patient at the time of chemotherapy initiation.  
After matching, differences in baseline characteristics between chemotherapy-
treated and no-chemotherapy patients were greatly reduced. Standardized differences 
were computed for each of the baseline variables before and after matching. The 
standardized differences after matching were less than 10% for all levels of baseline 
characteristics, indicating a good balance achieved through matching between the 
distribution of patient characteristics in the matched chemotherapy and no-chemotherapy 
cohorts (Table 4-1).  
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Table 4-1 Patient characteristics by adjuvant chemotherapy status before and after 
matching  
  Before Matching  After Matching 
 
All BC 
No 
CHEMO  
Any 
CHEMO SD  
No 
CHEMO  
Any 
CHEMO SD 
Sample size, n 84,018        
  
69,293             
  
14,725           
  
   14,024     14,024   
Age at diagnosis, yr.         
66-69 21.5 17.8 38.8 0.480  35.4 37.8 0.050 
70-74 27.6 26.1 34.3 0.179  35.1 34.6 0.010 
75-79 25.4 26.6 19.6 0.168  21.2 20.1 0.027 
80-84 17.3 19.6 6.2 0.409  6.1 6.4 0.012 
85-89 8.3 9.8 1.1 0.392  2.2 1.1 0.086 
Race         
White 90.2 90.8 87.6 0.101  88.1 87.8 0.008 
Black 5.8 5.3 7.8 0.101  7.6 7.7 0.003 
Other 4.0 3.9 4.5 0.031  4.3 4.5 0.008 
Marriage status         
Single 52.3 53.8 44.8 0.181  45.8 45.0 0.016 
Married 44.6 42.9 52.3 0.188  51.1 52.1 0.019 
Unknown 3.2 3.3 2.9 0.021  3.1 2.9 0.010 
Year of diagnosis         
1992 4.4 4.8 2.6 0.117  2.7 2.7  
1993 4.2 4.6 2.5 0.114  2.5 2.5  
1994 4.1 4.4 2.7 0.096  2.7 2.7  
1995 4.2 4.5 2.6 0.106  2.6 2.6  
1996 3.9 4.2 2.6 0.093  2.6 2.6  
1997 4.2 4.3 3.3 0.051  3.4 3.4  
1998 4.1 4.1 3.9 0.010  3.9 3.9  
1999 4.2 4.2 4.4 0.011  4.4 4.4  
2000 7.5 7.3 8.6 0.047  8.6 8.6  
2001 9.0 8.7 10.5 0.062  10.5 10.5  
2002 8.9 8.6 10.2 0.054  10.2 10.2  
2003 8.4 8.3 9.1 0.027  9.0 9.0  
2004 8.5 8.3 9.3 0.035  9.3 9.3  
2005 8.3 8.1 9.4 0.044  9.3 9.3  
2006 8.1 7.8 9.4 0.056  9.3 9.3  
2007 7.8 7.6 9.0 0.053  8.9 8.9  
SEER area         
California 31.7 32.0 30.3 0.037  30.6 30.6 0.000 
Connecticut 10.1 10.4 8.4 0.070  8.6 8.4 0.009 
Detroit 10.8 10.5 12.3 0.057  12.1 12.1 0.002 
Hawaii 1.8 1.8 2.1 0.025  1.9 2.1 0.014 
Iowa 10.8 11.3 8.5 0.093  8.6 8.7 0.006 
New Mexico 3.1 3.2 2.5 0.038  2.5 2.6 0.007 
Seattle 3.6 3.7 3.4 0.017  3.5 3.4 0.008 
Utah 3.8 3.6 4.3 0.035  4.2 4.3 0.005 
Atlanta/rural 
Georgia 
4.6 4.6 4.6 0.001  4.5 4.6 0.003 
Kentucky 5.4 5.3 5.8 0.022  6.2 5.7 0.019 
Louisiana 4.3 4.0 5.5 0.067  5.4 5.4 0.002 
New Jersey 10.0 9.6 12.3 0.087  11.9 12.1 0.006 
AJCC stage         
Stage I 57.4 65.6 19.0 1.069  18.9 19.8 0.022 
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Stage II 35.8 30.2 62.6 0.689  66.0 62.7 0.070 
Stage III 6.7 4.3 18.3 0.456  15.0 17.5 0.067 
Size, cm         
< 2 60.2 65.3 36.1 0.611  36.6 36.6 0.002 
≥ 2 37.4 32.3 61.6 0.616  61.3 61.1 0.004 
Unknown 2.4 2.5 2.3 0.012  2.0 2.3 0.018 
Positive lymph node        
Negative 62.6 68.5 34.7 0.721  36.9 36.0 0.019 
Positive 24.3 16.6 60.7 1.016  57.8 59.2 0.028 
Unknown 13.0 14.8 4.6 0.351  5.2 4.8 0.022 
Grade         
Well 21.7 24.3 9.2 0.411  10.7 9.6 0.036 
Moderately 40.8 42.0 35.0 0.143  37.3 35.7 0.033 
Poorly 25.3 20.9 46.0 0.553  42.0 44.8 0.058 
Undifferentiated 1.3 1.2 2.0 0.063  1.7 2.0 0.016 
Unknown 11.0 11.7 7.7 0.133  8.4 8.0 0.015 
Histology         
Ductal 69.1 68.5 71.8 0.071  70.1 71.6 0.032 
Lobular 10.0 9.9 10.4 0.016  11.4 10.6 0.024 
Mixed 10.5 10.5 10.3 0.005  10.6 10.4 0.008 
Unknown 10.4 11.1 7.5 0.124  7.9 7.4 0.017 
ER/PR status         
ER + and/or PR + 73.9 77.0 59.3 0.387  64.0 60.5 0.071 
ER- and PR- 12.6 8.9 30.1 0.556  24.6 28.6 0.091 
Unknown 13.5 14.1 10.6 0.108  11.4 10.8 0.019 
Laterality, right 51.1 51.0 51.9 0.018  51.1 51.8 0.014 
Surgery type/RT         
BCS with RT 37.6 39.5 28.7 0.231  31.8 29.1 0.059 
BCS without RT 15.7 16.2 13.6 0.071  11.6 13.6 0.061 
Mastectomy 46.7 44.3 57.7 0.271  56.6 57.3 0.014 
Comorbid conditions        
ASHD 14.7 15.3 11.8 0.103  12.2 11.7 0.015 
CHF 6.5 7.0 4.1 0.127  4.5 4.1 0.020 
CVA/TIA 5.8 6.2 4.1 0.097  4.3 4.1 0.010 
Dysrhythmia 12.7 13.5 9.0 0.142  9.8 9.0 0.025 
PVD 7.5 8.0 5.1 0.115  5.6 5.2 0.018 
Cardiac, other 10.9 11.3 9.2 0.070  9.9 9.2 0.023 
Anemia 9.0 9.3 7.8 0.055  8.1 7.7 0.017 
COPD 10.4 10.6 9.1 0.053  9.3 9.0 0.009 
Diabetes 16.3 16.1 17.5 0.039  17.9 17.3 0.015 
GI disorder 2.4 2.5 2.0 0.034  2.2 2.0 0.011 
Hypertension 54.6 54.8 53.6 0.025  54.0 53.3 0.013 
Note: Values are percentages unless otherwise indicated. Before matching, patient characteristic comparisons between 
chemotherapy treatment and no-treatment cohorts were statistically significant (P < 0.05) for all variables. Cox 
proportional hazards modeling including all the factors listed in this table as independent variables was used to estimate 
the probability of initiating adjuvant chemotherapy at each day within 6 months after first breast-conserving surgery or 
mastectomy for each patient. At each time point when one or more patients initiated adjuvant chemotherapy, patients 
who received chemotherapy on that day were individually matched using the Greedy Match algorithm performed 8->2 
digits with those who had the same or similar probability but had not yet initiated chemotherapy on that day. A 
standardized difference of less than 0.1 (10%) represents a rule-of-thumb for an acceptable balance in covariate 
distribution between treated and untreated subjects. 
 
Abbreviation: AJCC, American Joint Committee on Cancer; ASHD, atherosclerotic heart disease; BC, breast cancer; 
BCS, breast-conserving surgery; CHF, congestive heart failure; CHEMO, chemotherapy; COPD, chronic obstructive 
pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ER, estrogen receptor; GI, 
gastrointestinal; PR, progesterone receptor; PVD, peripheral vascular disease; SD, standardized difference.  
 59 
 
Of patients in the matched treatment cohort, 53.2%, 31.3%, 7.3%, and 8.1% 
received an anthracycline-based regimen, CMF (without anthracyclines), a taxane-based 
regimen (without anthracyclines and CMF), and other chemotherapy, respectively. 
Among 1,140 patients who received other chemotherapy, 769 (67%) received one or 
more different chemotherapeutic agents that could not be classified as one of the three 
major regimen types, and for 371 (33%) no chemotherapeutic agents were reported on 
Medicare claims. Trastuzumab, approved by the U.S. Food and Drug Administration 
(FDA) on November 16, 2006, as part a treatment regimen containing doxorubicin, 
cyclophosphamide, and paclitaxel for the adjuvant treatment of women with node-
positive, HER2-overexpressing breast cancer, was used most often with a taxane-based 
regimen (29.1%), followed by other chemotherapy (11.2%), an anthracycline-based 
regimen (5.1%), and CMF (0.3%). The proportion of trastuzumab use in patients treated 
with adjuvant chemotherapy was low (< 2.5%) before 2005, but increased rapidly from 
12.5% in 2005 to about 20% in 2008.  
 Figure 4-2 presents the trends in use of the major types of chemotherapy by year 
of initiation. Use of anthracycline-based chemotherapy increased steadily from 1992 to 
2005, and decreased after 2005. CMF regimens had been the major choice of treatment in 
the 1990s; more than half of chemotherapy-treated patients received CMF, but use 
decreased rapidly after 1999 and occurred for only 7% of patients who initiated adjuvant 
chemotherapy in 2008. Use of non-anthracycline-containing taxane-based chemotherapy 
was not common before 2005, but increased sharply from 4.4% in 2005 to 50% in 2008. 
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Figure 4-2 Trends in use of major chemotherapy regimen types by year of initiation of 
adjuvant chemotherapy 
 
The balance in the distribution of patient characteristics between the matched 
chemotherapy-treatment and no-treatment cohorts was apparently not preserved for each 
type of adjuvant chemotherapy compared with no treatment (Table 4-2). Compared with 
patients in the matched untreated cohort, patients receiving anthracycline-based 
chemotherapy were younger, diagnosed at a later stage, more likely to have positive 
lymph nodes, more likely to be hormone receptor negative, and less likely to have 
comorbid conditions at baseline. Conversely, patients receiving anthracycline-free 
taxane-based chemotherapy, were older, more likely to have negative lymph nodes, and 
more likely to have comorbid conditions.   
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Table 4-2 Baseline characteristics of the matched no-chemotherapy and chemotherapy 
cohorts by type of chemotherapy  
 Matched No 
CHEMO  
Matched CHEMO  
 Anthracyclines  CMF Taxane Others P 
Sample size, n 14,024 7,465 4,389 1,030 1,140  
Trastuzumab use  5.1 0.3 29.1 11.2  
Age at diagnosis, yr.      <0.001 
66-69 35.4 44.7 30.3 30.1 28.3  
70-74 35.0 34.7 35.3 35.3 30.1  
75-79 21.2 17.1 24.2 21.4 22.8  
80-84 6.1 3.1 9.1 11.0 14.0  
85-89 2.2 0.4 1.3 2.2 4.7  
Race      0.48 
White 88.1 87.9 88.3 86.2 87.4  
Black 7.6 7.6 7.2 8.7 8.8  
Other 4.3 4.5 4.6 5.0 3.9  
Marriage status      <0.001 
Single 45.8 42.7 47.2 45.5 51.1  
Married 51.1 54.5 49.7 50.9 46.6  
Unknown 3.1 2.9 3.1 3.6 2.3  
Year of diagnosis      <0.001 
1992 2.7 0.8 5.0  7.7  
1993 2.5 1.1 5.3  3.9  
1994 2.7 1.2 5.1  5.6  
1995 2.6 1.2 5.0 * 5.1  
1996 2.6 1.4 4.6 * 4.9  
1997 3.4 2.4 5.7 * 3.6  
1998 3.9 2.7 7.1 * 2.2  
1999 4.4 4.4 5.9 * 2.0  
2000 8.6 9.0 10.3 2.9 4.8  
2001 10.5 10.4 11.8 4.2 11.2  
2002 10.2 10.2 11.0 4.8 12.1  
2003 9.0 10.7 7.2 5.0 8.9  
2004 9.3 12.8 5.6 5.1 4.6  
2005 9.3 12.6 4.3 7.8 8.3  
2006 9.3 10.9 3.6 23.8 7.4  
2007 8.9 8.0 2.6 44.4 7.7  
SEER area      <0.001 
California 30.6 30.9 27.2 39.0 33.9  
Connecticut 8.6 7.0 12.2 4.8 6.1  
Detroit 12.1 11.3 14.9 7.5 11.1  
Hawaii 1.9 2.0 2.5 * 2.6  
Iowa 8.6 8.5 10.2 3.9 8.7  
New Mexico 2.5 2.4 2.4 ** 4.6  
Seattle 3.5 3.3 3.1 5.9 3.1  
Utah 4.2 4.2 5.1 2.3 3.6  
Atlanta/rural 
Georgia 
4.5 4.1 5.2 5.1 4.8  
Kentucky 6.2 6.7 4.1 7.1 3.9  
Louisiana 5.4 6.6 2.3 7.9 6.9  
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New Jersey 11.9 12.9 10.7 14.0 10.5  
AJCC stage      <0.001 
I 18.9 16.2 23.5 25.2 24.6  
II 66.0 62.9 66.2 52.5 56.6  
III 15.0 20.9 10.3 22.3 18.8  
Size, cm      <0.001 
< 2 36.6 34.8 39.7 35.9 36.3  
≥ 2 61.3 62.5 58.8 62.1 60.0  
Unknown 2.0 2.7 1.4 1.9 3.7  
Positive lymph node     <0.001 
Negative 36.9 31.4 41.7 44.3 36.6  
Positive 57.8 64.2 54.3 49.6 54.2  
Unknown 5.2 4.3 4.0 6.1 9.2  
Grade      <0.001 
Well 10.7 9.7 10.1 7.2 9.0  
Moderately 37.3 36.6 34.2 36.0 34.7  
Poorly 42.0 45.6 42.7 50.9 42.7  
Undifferentiated 1.8 1.9 2.2 1.8 1.9  
Unknown 8.4 6.2 10.9 4.2 11.6  
Histology      <0.001 
Ductal 70.1 71.0 71.2 76.2 72.3  
Lobular 11.4 10.7 11.2 8.3 9.6  
Mixed 10.6 11.2 9.7 8.7 9.6  
Unknown 7.9 7.1 7.9 6.8 8.6  
ER/PR status      <0.001 
ER + and/or PR + 64.0 62.6 57.6 57.2 61.6  
ER- and PR- 24.6 27.9 29.2 36.1 24.5  
Unknown 11.4 9.5 13.2 6.7 13.9  
Laterality, right 51.1 52.3 50.6 52.2 53.2 0.22 
Surgery type/RT      <0.001 
BCS with RT 31.8 30.3 26.8 30.4 29.4  
BCS without RT 11.6 13.6 13.3 16.5 12.4  
Mastectomy 56.6 56.1 59.9 53.1 58.2  
Comorbid conditions      
ASHD 12.2 9.8 14.0 14.0 13.0 <0.001 
CHF 4.5 2.6 5.4 6.9 6.3 <0.001 
CVA/TIA 4.3 3.8 3.9 5.0 5.3 0.09 
Dysrhythmia 9.8 7.4 10.3 12.8 11.8 <0.001 
PVD 5.6 4.6 5.1 7.8 6.8 <0.001 
Cardiac, other 9.9 8.4 9.6 12.8 9.6 <0.001 
Anemia 8.1 7.2 7.3 9.2 10.4 <0.001 
COPD 9.3 8.9 8.6 11.2 9.1 0.13 
Diabetes 17.9 16.7 17.6 21.4 17.1 0.004 
GI disorder 2.2 1.8 2.2 1.7 2.6 0.22 
Hypertension 54.0 52.6 52.2 65.7 50.9 <0.001 
Note: Values are % unless otherwise indicated.  
Abbreviation: AJCC, American Joint Committee on Cancer; ASHD, atherosclerotic heart disease; BCS, breast-
conserving surgery; CHF, congestive heart failure; CMF, cyclophosphamide, methotrexate, and fluorouracil; CHEMO, 
chemotherapy; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic 
attack; ER, estrogen receptor; GI, gastrointestinal; PR, progesterone receptor; PVD, peripheral vascular disease. 
* Values for cells with ten or fewer patients are suppressed.  
** Value is suppressed to avoid deriving other cell with ten or fewer patients.  
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4.2 Objective 1 – Adjuvant Chemotherapy and Risk of Acute Kidney 
Injury 
4.2.1 Any Chemotherapy and Risk of Acute Kidney Injury 
The mean (standard deviation [SD]) follow-up time was 179.5 (23.5) days for the 
chemotherapy treated cohort and 130.1 (75.1) days for the matched no-chemotherapy 
cohort. During the maximum 6-month follow-up period, AKI occurred in 140 (0.5%) 
patients, 0.78% of patients who received adjuvant chemotherapy (n = 110) and 0.21% of 
patients who did not (n = 30). The AKI rate measured as number of patients who 
developed AKI divided by total patient-years at risk was 15.9 per 1,000 patient-years in 
the treatment cohort and 6.0 per 1,000 patient-years in the no-treatment cohort.  
Figure 4-3 presents Kaplan-Meier estimated cumulative percent of patients 
developing AKI during the follow-up period by chemotherapy use. During the follow-up 
period, risk of AKI was consistently higher for patients receiving than not receiving 
adjuvant chemotherapy (P < 0.0001). The cumulative percentages of patients with AKI at 
days 30, 90, and 180 were 0.24%, 0.50%, and 0.80% for patients receiving adjuvant 
chemotherapy, compared with 0.05%, 0.17%, and 0.30% for no-chemotherapy patients. 
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Figure 4-3 Cumulative percent of patients developing AKI during the 6-month follow-up 
period, by adjuvant chemotherapy status 
 
 
 
A Cox proportional hazards model was performed to evaluate the risk of incident 
AKI following adjuvant chemotherapy. Patients who received adjuvant chemotherapy 
were almost 3 times (hazards ratio [HR] 2.73, 95% confidence interval [CI] 1.82-4.09; P 
< 0.001) more likely to develop incident AKI than patients who did not. Adjustment for 
patient demographics, tumor characteristics, and comorbid conditions had miniscule 
impact on the estimated HR described above, indicating good balance achieved through 
matching in the distribution of baseline variables between treated and untreated patients 
(Table 4-3). Significant predictors for incident AKI following chemotherapy initiation 
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included increasing age at diagnosis, black race, breast-conserving surgery without 
radiation therapy, and atherosclerotic heart disease (Table 4-3).  
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Table 4-3 Adjusted hazard ratios for the association of adjuvant chemotherapy, 
demographics, tumor characteristics, and comorbid conditions with incident acute kidney 
injury  
Variable Hazard ratio 95% CI P 
Chemotherapy              2.69  (1.79, 4.06) <0.001 
Age at diagnosis, yrs.    
66-69 Reference   
70-74           1.33  (0.83, 2.13) 0.24 
75-79           1.95  (1.21, 3.15) <0.01 
80-84           2.03  (1.09, 3.79) 0.03 
85-89           2.65  (1.05, 6.66) 0.04 
Race    
White Reference   
Black           1.83  (1.15, 2.94) 0.01 
Other           0.98  (0.37, 2.56) 0.96 
Marriage status    
Married Reference   
Single           1.19  (0.83, 1.70) 0.35 
Unknown           1.32  (0.55, 3.15) 0.53 
Diagnosis year    
1992 Reference   
1993           4.31  (0.48, 38.75) 0.20 
1994           1.64  (0.15, 18.19) 0.69 
1995           2.89  (0.30, 28.07) 0.36 
1996           2.92  (0.30, 28.35) 0.35 
1997           2.09  (0.21, 20.32) 0.53 
1998           1.91  (0.20, 18.62) 0.58 
1999           2.16  (0.24, 19.60) 0.50 
2000           3.12  (0.39, 24.69) 0.28 
2001           2.51  (0.31, 20.03) 0.39 
2002           1.28  (0.15, 11.21) 0.82 
2003           5.14  (0.67, 39.38) 0.11 
2004           3.17  (0.40, 24.90) 0.27 
2005           3.91  (0.50, 30.30) 0.19 
2006           4.75  (0.62, 36.60) 0.13 
2007           6.85  (0.90, 52.13) 0.06 
SEER area    
California Reference   
Connecticut 0.76 (0.37, 1.59) 0.47 
Detroit 1.63 (1.00, 2.66) 0.05 
Hawaii 1.33 (0.35, 5.06) 0.68 
Iowa 0.43 (0.15, 1.21) 0.11 
Kentucky 0.95 (0.45, 1.99) 0.89 
Louisiana 1.25 (0.67, 2.33) 0.48 
New Jersey 0.75 (0.43, 1.32) 0.32 
New Mexico 0.62 (0.15, 2.58) 0.51 
Seattle 0.23 (0.03, 1.68) 0.15 
Utah 0.70 (0.22, 2.27) 0.55 
Atlanta/rural Georgia 0.15 (0.02, 1.06) 0.06 
AJCC stage    
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Stage I Reference   
Stage II           0.85  (0.42, 1.71) 0.64 
Stage III           1.19  (0.52, 2.72) 0.68 
Tumor size, cm    
< 2 Reference   
≥ 2           1.52  (0.94, 2.45) 0.09 
Unknown           0.92  (0.25, 3.32) 0.89 
Positive lymph nodes   
Negative Reference   
Positive           1.44  (0.87, 2.38) 0.15 
Unknown           1.50  (0.73, 3.10) 0.27 
Grade    
Well Reference   
Moderately           1.53  (0.71, 3.30) 0.28 
Poorly           2.13  (0.99, 4.56) 0.05 
Undifferentiated           1.58  (0.33, 7.58) 0.57 
Unknown           1.82  (0.69, 4.80) 0.23 
Histology    
Ductal Reference   
Lobular           0.80  (0.43, 1.51) 0.50 
Mixed           0.58  (0.30, 1.13) 0.11 
Unknown           0.88  (0.45, 1.72) 0.70 
ER/PR status    
ER + and/or PR + Reference   
ER- and PR-           0.71  (0.46, 1.08) 0.11 
Unknown           0.96  (0.56, 1.64) 0.87 
Laterality    
Left Reference   
Right           1.03  (0.74, 1.43) 0.87 
Surgery type/RT    
BCS and RT Reference   
BCS, no RT           2.24  (1.31, 3.84) <0.01 
Mastectomy           1.27  (0.80, 2.03) 0.31 
Comorbid conditions   
ASHD           1.81  (1.19, 2.75) <0.01 
CHF           1.66  (0.97, 2.86) 0.07 
CVA/TIA           1.29  (0.72, 2.32) 0.39 
Dysrhythmia           1.26  (0.78, 2.03) 0.35 
PVD           1.20  (0.70, 2.06) 0.52 
Cardiac, other           1.15  (0.71, 1.86) 0.57 
Anemia           1.00  (0.60, 1.66) 1.00 
COPD           0.88  (0.52, 1.50) 0.65 
Diabetes           1.42  (0.97, 2.08) 0.07 
GI disorder           1.36  (0.55, 3.40) 0.51 
Hypertension           1.19  (0.80, 1.77) 0.40 
Abbreviation: AJCC, American Joint Committee on Cancer; ASHD, atherosclerotic heart disease; BCS, 
breast-conserving surgery; CHF, congestive heart failure; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ER, estrogen 
receptor; GI, gastrointestinal; PR, progesterone receptor; PVD, peripheral vascular disease; RT, radiation 
therapy. 
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4.2.2 Regimen Type and Risk of Acute Kidney Injury 
Figure 4-4 presents Kaplan-Meier estimated cumulative percentages of patients 
who received anthracyclines, CMF, taxane, and other chemotherapy developing AKI 
during the follow-up period compared with no-chemotherapy patients. During the 6-
month follow-up period, rates of AKI were consistently higher for patients who received 
taxane-based chemotherapy, followed by rates for patients who received other 
chemotherapy. Cumulative incidence of AKI was similar for patients treated with 
anthracyclines and CMF. The estimated 6-month cumulative incidence of AKI was 2.0%, 
1.0%, 0.7%, and 0.6% for patients treated with taxane, other chemotherapy, 
anthracyclines, and CMF, respectively, compared with 0.3% in no-chemotherapy patients 
(P < 0.0001). 
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Figure 4-4 Cumulative percent of patients developing AKI during the 6-month follow-up 
period, by regimen 
 
 
The association between adjuvant chemotherapy and risk of AKI varied across 
regimen types (Table 4-4). After adjustment for baseline characteristics and trastuzumab 
use, patients treated with taxane-based chemotherapy were about 4 times more likely to 
develop AKI than untreated patients (HR 4.17, 95% CI 2.23-7.79); this relationship was 
the most profound association among the four types of treatment. Patients who received 
other chemotherapy were about 3 times more likely to develop AKI than patients who did 
not receive adjuvant chemotherapy (HR 3.01, 95% CI 1.47-6.16). The hazards ratio of 
AKI was similar for patients treated with anthracycline-based chemotherapy (HR 2.54, 
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95% CI 1.60-4.06) and CMF (HR 2.22, 95% CI 1.30-3.82) compared with no-
chemotherapy patients.  
The effect of trastuzumab use on risk of AKI was evaluated among patients who 
received adjuvant chemotherapy (Table 4-4). After adjustment for baseline characteristics 
and types of chemotherapy, use of trastuzumab was associated with a 6% increased risk 
of AKI, but this association was not significant (P = 0.87).
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Table 4-4 Association between type of adjuvant chemotherapy and risk of acute kidney injury during the 6-month follow-up  
  Patients Mean (SD) Unadjusted  Adjusted  
Regimen Total, n with AKI, n (%) F/U time, days HR (95% CI) P HR (95% CI) P 
Both cohorts*        
No chemotherapy 14024 30 (0.21) 130 (75) Reference  Reference  
Anthracyclines 7465 53 (0.71) 180 (22) 2.46 (1.57, 3.85) <0.001 2.54 (1.60, 4.06) <0.001 
CMF 4389 26 (0.59) 180 (22) 2.06 (1.22, 3.48) 0.007 2.22 (1.30, 3.82) 0.004 
Taxane 1030 20 (1.94) 177 (29) 6.84 (3.88, 12.05) <0.001 4.17 (2.23, 7.79) <0.001 
Others 1140 11 (0.96) 176 (33) 3.42 (1.72, 6.83) <0.001 3.01 (1.47, 6.16) 0.003 
Treatment cohort†        
No trastuzumab 13198 98 (0.74) 180 (23) Reference  Reference  
Trastuzumab 826 12 (1.45) 179 (27) 1.97 (1.08, 3.59) 0.026 1.06 (0.55, 2.08) 0.85 
*All patients in the matched chemotherapy treatment and no-treatment cohorts were included in this analysis. Covariates in the model include factors listed in 
Table 4-1 and trastuzumab use.  
†All patients in the matched chemotherapy treatment cohort were included in this analysis. Covariates in the model include factors listed in Table 4-1 and type of 
regimen.  
Abbreviation: AKI, acute kidney injury; CI, confidence interval; CMF, cyclophosphamide, methotrexate, and fluorouracil; F/U, follow-up; HR, hazard ratio. 
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4.2.3 AKI Case Studies 
More AKI patients in the chemotherapy cohort than in the matched no-
chemotherapy cohort were older and black, and had stage I cancer, negative hormone 
receptor, and comorbid conditions including CHF, dysrhythmia, diabetes, and 
hypertension at baseline, but these comparisons were not statistically significant due to 
small sample size. 
AKI was coded as the principal diagnosis on hospital claims in 21.5% of AKI 
patients who received adjuvant chemotherapy and in 10.3% of AKI patients who did not. 
Unspecified AKI (ICD-9-CM code 584.9) was the most frequent AKI diagnosis, 
representing 82.2% of chemotherapy-treated patients with AKI and 86.2% of untreated 
patients with AKI. AKI with lesion of tubular necrosis (ICD-9-CM code 584.5) was 
diagnosed in 16.8% of chemotherapy-treated patients with AKI and in 10.3% of untreated 
patients with AKI. 
Among 84 AKI patients who received chemotherapy and for whom AKI was a 
secondary diagnosis, septicemia (ICD-9-CM code 038.xx) was coded most frequently as 
the principal diagnosis in 27.4%, followed by disorder of fluid, electrolyte, and acid-base 
balance (ICD-9-CM code 276.xx) in 9.5%, and other disease of lung (ICD-9-CM code 
518.xx) in 6.0%. Among 26 AKI patients who did not receive chemotherapy and for 
whom AKI was a secondary diagnosis, septicemia was coded most frequently as the 
principal diagnosis in 15.4%. Disorder of fluid, electrolyte, and acid-base balance, female 
breast cancer (ICD-9-CM code 276), unspecified pneumonia (ICD-9-CM code 486), 
other chronic ischemic heart disease (ICD-9-CM code 414), and endocarditis (ICD-9-CM 
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code 421) were diagnosed in 7.7%, respectively. 
Regardless of position on the hospital claims, 96.3% of AKI patients treated with 
chemotherapy were also diagnosed with disorder of fluid, electrolyte, and acid-base 
balance, compared with 86.2% of AKI patients not treated with chemotherapy. 
Septicemia was the second most commonly diagnosed disease in chemotherapy-treated 
patients with AKI, representing 40.2% of these cases, but it occurred in only 17.2% of 
AKI patients who did not receive chemotherapy. 
4.3 Objective 2 – Adjuvant Chemotherapy and Risk of Chronic Kidney 
Disease 
4.3.1 Any Chemotherapy and Risk of CKD 
The mean (SD) follow-up time was 5.06 (3.39) years for the chemotherapy-
treated cohort and 3.25 (3.6) years for the untreated cohort. During the maximum 18-year 
follow-up period, CKD occurred in 2,058 patients (14.7%) who received adjuvant 
chemotherapy and in 1,335 patients (9.5%) who did not. CKD rates (SE) were 29.0 (0.6) 
per 1,000 patient-years in the treatment cohort and 29.3 (0.8) per 1,000 patient-years in 
the no-treatment cohort. Among patients in the matched chemotherapy cohort, 20.9% 
died, 9.4% changed Medicare fee-for-service enrollment status, 6.2% developed a non-
breast primary cancer, and nearly 50% were followed until the end of study (December 
31, 2009). Among patients in the matched no-chemotherapy cohort, nearly one-third 
initiated adjuvant chemotherapy within 6 months of first surgery, 6.6% underwent first 
chemotherapy treatment more than 6 months after first surgery, 12.6% died, 6.3% 
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changed Medicare fee-for-service enrollment status, 4.2% developed a non-breast 
primary cancer, and 28.8% were followed until the end of study.   
Figure 4-5 shows the Kaplan-Meier estimated cumulative percent of patients 
developing CKD during the follow-up period by chemotherapy use. Overall, there was no 
significant difference in the cumulative incidence of CKD between patients who received 
adjuvant chemotherapy and patients who did not (P = 0.91). Within the first 14 years of 
follow-up, all patients had similar rates of CKD; the 14-year cumulative percentages of 
patients developing CKD were 37.9% in chemotherapy-treated patients and 36.2% in no-
chemotherapy patients. Beyond 14 years, the cumulative incidence of CKD was slightly 
higher in patients who were treated with adjuvant chemotherapy than in patients who 
were not. However, these results were based on 274 chemotherapy-treated patients and 
200 untreated patients. The cumulative percentages of patients developing CKD by the 
end of follow-up were 47.2% in chemotherapy-treated patients and 49% in no-
chemotherapy patients. 
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Figure 4-5 Cumulative percent of patients developing chronic kidney disease, by adjuvant 
chemotherapy status 
 
 
A Cox proportional hazards model was performed to evaluate the risk of 
developing CKD following adjuvant chemotherapy. There was no significant difference 
between patients who received adjuvant chemotherapy and patients who did not (HR 
1.00, 95% CI 0.93-1.07; P = 0.91). Adjustment for patient demographics, tumor 
characteristics, and comorbid conditions did not change this association (Table 4-5). 
Significant predictors of developing CKD included increasing age at diagnosis, black 
race, single status, diagnosis at later tumor stage, breast-conserving surgery without 
radiation therapy and mastectomy regardless of radiation therapy, and presence of 
comorbid conditions including atherosclerotic heart disease, CHF, dysrhythmia, PVD, 
anemia, COPD, diabetes, and hypertension (Table 4-5).  
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Table 4-5 Adjusted hazard ratios for the association of adjuvant chemotherapy, 
demographics, tumor characteristics, and comorbid conditions with incident chronic 
kidney disease 
 Hazard ratio 95% CI P 
Chemotherapy 1.00 (0.93, 1.08) 0.99 
Age at diagnosis, yrs.    
66-69 Reference   
70-74 1.20 (1.1, 1.31) <0.001 
75-79 1.35 (1.22, 1.48) <0.001 
80-84 1.68 (1.46, 1.93) <0.001 
85-89 1.78 (1.41, 2.25) <0.001 
Race    
White Reference   
Black 1.26 (1.12, 1.42) <0.001 
Other 0.91 (0.75, 1.12) 0.36 
Marriage status    
Married Reference   
Single 1.12 (1.04, 1.20) 0.002 
Unknown 1.08 (0.89, 1.31) 0.45 
Diagnosis year    
1992 Reference   
1993 0.94 (0.71, 1.26) 0.68 
1994 1.19 (0.90, 1.57) 0.22 
1995 1.23 (0.93, 1.62) 0.15 
1996 1.36 (1.03, 1.81) 0.03 
1997 1.62 (1.24, 2.10) <0.001 
1998 1.39 (1.07, 1.81) 0.01 
1999 1.54 (1.19, 2.00) 0.001 
2000 1.86 (1.47, 2.36) <0.001 
2001 2.00 (1.58, 2.54) <0.001 
2002 1.96 (1.54, 2.49) <0.001 
2003 2.30 (1.80, 2.94) <0.001 
2004 2.32 (1.81, 2.98) <0.001 
2005 2.47 (1.91, 3.18) <0.001 
2006 2.42 (1.86, 3.14) <0.001 
2007 2.96 (2.26, 3.88) <0.001 
SEER area    
California Reference   
Connecticut 1.01 (0.88, 1.16) 0.88 
Detroit 1.09 (0.98, 1.22) 0.12 
Hawaii 0.94 (0.70, 1.25) 0.66 
Iowa 0.86 (0.75, 0.99) 0.03 
Kentucky 1.04 (0.89, 1.22) 0.61 
Louisiana 1.06 (0.90, 1.24) 0.50 
New Jersey 0.90 (0.80, 1.02) 0.10 
New Mexico 0.85 (0.67, 1.08) 0.18 
Seattle 1.05 (0.85, 1.29) 0.67 
Utah 0.72 (0.58, 0.89) 0.002 
Atlanta/rural Georgia 1.11 (0.94, 1.31) 0.20 
AJCC stage    
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Stage I Reference   
Stage II 1.10 (0.97, 1.25) 0.15 
Stage III 1.30 (1.10, 1.54) 0.002 
Tumor size, cm    
< 2 Reference   
≥ 2 1.04 (0.95, 1.14) 0.37 
Unknown 1.19 (0.94, 1.50) 0.15 
Positive lymph nodes   
Negative Reference   
Positive 1.03 (0.93, 1.13) 0.60 
Unknown 1.20 (1.03, 1.4) 0.02 
Grade    
Well Reference   
Moderately 1.00 (0.89, 1.13) 0.99 
Poorly 1.10 (0.97, 1.24) 0.13 
Undifferentiated 0.98 (0.73, 1.3) 0.87 
Unknown 0.99 (0.85, 1.17) 0.94 
Histology    
Ductal Reference   
Lobular 1.11 (0.99, 1.24) 0.08 
Mixed 1.05 (0.94, 1.17) 0.43 
Unknown 1.02 (0.9, 1.16) 0.76 
ER/PR status    
ER + and/or PR + Reference   
ER- and PR- 1.00 (0.92, 1.1) 0.97 
Unknown 1.05 (0.95, 1.17) 0.35 
Laterality    
Left Reference   
Right 0.95 (0.89, 1.02) 0.13 
Surgery type/RT    
BCS and RT Reference   
BCS, no RT 1.19 (1.06, 1.34) 0.004 
Mastectomy 1.22 (1.12, 1.33) <0.001 
Comorbid conditions   
ASHD 1.22 (1.11, 1.34) <0.001 
CHF 1.61 (1.41, 1.84) <0.001 
CVA/TIA 1.05 (0.9, 1.22) 0.55 
Dysrhythmia 1.13 (1.01, 1.26) 0.03 
PVD 1.22 (1.07, 1.38) 0.003 
Cardiac, other 1.10 (0.99, 1.23) 0.09 
Anemia 1.30 (1.16, 1.45) <0.001 
COPD 1.13 (1.01, 1.26) 0.04 
Diabetes 2.15 (1.99, 2.33) <0.001 
GI disorder 1.14 (0.94, 1.39) 0.19 
Hypertension 1.49 (1.38, 1.61) <0.001 
Abbreviation: AJCC, American Joint Committee on Cancer; ASHD, atherosclerotic heart disease; BCS, 
breast-conserving surgery; CHF, congestive heart failure; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ER, estrogen 
receptor; GI, gastrointestinal; PR, progesterone receptor; PVD, peripheral vascular disease; RT, radiation 
therapy. 
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4.3.2 Type of Chemotherapy and Risk of CKD 
Figure 4-6 shows the Kaplan-Meier estimated cumulative percent of patients 
developing CKD during the follow-up period by type of chemotherapy. Compared with 
patients who did not receive adjuvant chemotherapy, rates of CKD were significantly 
higher for patients who received taxane-based chemotherapy (P = 0.0005); rates were 
similar for patients who received an anthracycline-based regimen, CMF, and other types 
of chemotherapy (P = 0.71).  
 
Figure 4-6 Cumulative percent of patients developing chronic kidney disease, by type of 
adjuvant chemotherapy 
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*Value for cell with ten or fewer patients is suppressed. 
0
10
20
30
40
50
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
C
um
ul
at
iv
e p
er
ce
nt
 o
f C
K
D
Years of follow-up
Taxane
Other
Anthracycline
CMF
No CHEMO
 79 
 
Table 4-6 presents the association between adjuvant chemotherapy and risk of 
developing CKD by regimen and trastuzumab use. Because the interaction term in the 
model for regimen and trastuzumab use and risk of CKD was not significant (P = 0.70), 
the effect of regimen on risk of CKD was evaluated after adjustment for patient baseline 
characteristics and trastuzumab use. Compared with patients who did not receive 
adjuvant chemotherapy, patients treated with CMF and patients treated with other 
chemotherapy were 4% more likely to develop CKD; patients treated with anthracycline-
based regimens were 4% less likely and patients treated with taxane-based regimens were 
9% less likely to develop CKD. Though the association between adjuvant chemotherapy 
and risk of developing CKD varied across regimen types, these associations were not 
statistically significant.  
The effect of trastuzumab use on risk of CKD was evaluated among patients 
treated with adjuvant chemotherapy. Compared with patients who did not receive 
trastuzumab, patients who did were 18% more likely to develop CKD (HR 1.18, 95% CI 
0.94-1.47), but this association was not significant.  
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Table 4-6 Type of adjuvant chemotherapy and trastuzumab use and associated risks of chronic kidney disease 
  Patients w/ Mean (SD) Rate of CKD Unadjusted  Adjusted  
Treatment Total, n CKD, n (%) F/U time, years  (1000 pt/yrs) HR (95% CI) P HR (95% CI) P 
Both cohorts*         
No chemotherapy 14024 1335 (9.5) 3.3 (3.6) 29.3 Reference  Reference  
Anthracyclines 7465 1001 (13.4) 4.8 (3.0) 27.7 0.97 (0.89, 1.05) 0.46 0.96 (0.88, 1.04) 0.31 
CMF 4389 762 (17.4) 6.0 (3.9) 29.1 0.97 (0.89, 1.06) 0.55 1.04 (0.95, 1.14) 0.44 
Taxane 1030 114 (11.1) 2.8 (1.8) 39.4 1.44 (1.19, 1.75) 0.0002 0.91 (0.74, 1.12) 0.38 
Others 1140 181 (15.9) 5.1 (4.0) 31.2 1.05 (0.90, 1.23) 0.55 1.04 (0.89, 1.22) 0.60 
Treatment cohort†         
No trastuzumab 13198 1956 (14.8) 5.2 (3.4) 28.5 Reference  Reference  
Trastuzumab 826 102 (12.3) 2.9 (1.6) 42.7 1.65 (1.35, 2.02) <.0001 1.18 (0.94, 1.47) 0.15 
*All patients in the matched chemotherapy-treatment and no-treatment cohorts were included in this analysis. Covariates in the model include factors listed in 
Table 4-1 and trastuzumab use.  
†All patients in the matched chemotherapy-treatment cohort were included in this analysis. Covariates in the model include factors listed in Table 4-1 and type of 
regimen.  
Abbreviation: CI, confidence interval; CKD, chronic kidney disease; CMF, cyclophosphamide, methotrexate, and fluorouracil; F/U, follow-up; HR, hazard ratio; 
SD, standard deviation.
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4.3.3 Sensitivity Analyses 
4.3.3.1 Adjuvant Chemotherapy as Time-Varying Variable 
Of 84,018 patients who met the study inclusion and exclusion criteria, 14,725 
received adjuvant chemotherapy. With initiation of adjuvant chemotherapy defined as a 
time-varying variable, the unadjusted hazard ratio of CKD was 0.98 (95% CI 0.93-1.02). 
After adjustment for patient demographics, tumor characteristics, and baseline comorbid 
conditions, adjuvant chemotherapy was associated with a 4% decreased risk of 
developing CKD compared with no adjuvant chemotherapy, and this association was not 
significant (HR 0.96, 95% CI 0.91-1.02; P = 0.19). 
4.3.3.2 Competing Risk Analyses 
The risk of CKD associated with adjuvant chemotherapy based on the competing 
risk analyses was qualitatively unchanged. The unadjusted hazards ratio of CKD for 
patients who received adjuvant chemotherapy compared with patients who did not was 
0.99 (95% CI 0.92-1.06; P = 0.77). After adjustment for patient baseline characteristics, 
the hazards ratio was 1.03 (95% CI 0.96-1.11; P = 0.42).  
4.3.3.3 Subgroup Analyses by Duration of Chemotherapy Course 
Among 14,024 patients who received adjuvant chemotherapy, 612 (4.4%) 
received ≤ 1 week of adjuvant chemotherapy; 584 (95%) of these received one treatment 
cycle only. Baseline characteristics differed substantially between patients in the shorter 
and in the longer chemotherapy subgroups. More patients in the shorter than in the longer 
treatment subgroup were aged 80 years or older (19% vs. 7%) and black (10% vs. 8%), 
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and had stage I tumors (33% vs. 19%), tumor size smaller than 2 cm (41% vs. 36%), 
negative lymph nodes (45% vs. 36%), and diabetes (20% vs. 17%) and cardiovascular 
disease (16% vs. 12% for ASHD; 15% vs. 9% for dysrhythmia; 9% vs. 4% for CHF).  
The association between adjuvant chemotherapy and risk of CKD varied across 
the subgroups of patients who received ≤ 1 week and > 1 week of chemotherapy 
compared with matched untreated patients. Patients who received ≤ 1 week of 
chemotherapy treatment had a 39% increased risk of CKD (HR 1.39, 95% CI 1.01-1.91; 
P = 0.042) compared with matched untreated patients, and this association was 
significant. Patients who received chemotherapy for > 1 week had a 3% reduced risk of 
CKD (HR 0.97, 95% CI 0.90-1.04; P = 0.35), but this association was not significant.  
4.4 Objective 3 – Utilization of Kidney Function Monitoring 
4.4.1 Patient Characteristics 
Of 28,048 patients in the matched cohorts, 23,096 were available for evaluation of 
kidney function monitoring, 13,818 (98.5% of 14,024) in the adjuvant chemotherapy 
cohort and 9,278 (66.2% of 14,024) in the no-treatment cohort. The mean (SD) follow-up 
time was 4.65 (3.40) years for patients in the chemotherapy cohort and 4.57 (3.43) years 
for patients in the no-treatment cohort. 
Since the follow-up start date in this study was no longer the date of initiation of 
adjuvant chemotherapy for patients in the treatment cohort and the matched date for 
patients in the no-treatment cohort, the balance in patient characteristics achieved from 
matching may not be preserved. Table 4-7 presents the distributions of selected patient 
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characteristics with significant differences between patients who received adjuvant 
chemotherapy and patients who did not. Patients who received chemotherapy, compared 
with patients who did not, were younger, more often black, diagnosed at a later stage, 
more likely to be hormone receptor negative, more likely to undergo mastectomy, and 
less likely to have cardiovascular disease at baseline.  
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Table 4-7 Baseline patient characteristics 
 No CHEMO  CHEMO  
 n %  n % P 
Total 9278 100.0  13818 100.0  
Age at diagnosis, yrs.      <0.001 
66-69 2817 30.4  5231 37.9  
70-74 3255 35.1  4780 34.6  
75-79 2205 23.8  2775 20.1  
80-84 712 7.7  880 6.4  
85-89 289 3.1  152 1.1  
Race      0.02 
White 8269 89.1  12152 87.9  
Black 634 6.8  1044 7.6  
Other 375 4.0  622 4.5  
Marriage status      0.003 
Single 4343 46.8  6214 45.0  
Married 4633 49.9  7203 52.1  
Unknown 302 3.3  401 2.9  
SEER registry      <0.001 
California 2926 31.5  4232 30.6  
Connecticut 818 8.8  1155 8.4  
Detroit 1017 11.0  1669 12.1  
Hawaii 143 1.5  290 2.1  
Iowa 889 9.6  1215 8.8  
New Mexico 239 2.6  355 2.6  
Seattle 336 3.6  466 3.4  
Utah 382 4.1  599 4.3  
Atlanta/rural Georgia 442 4.8  633 4.6  
Kentucky 589 6.4  798 5.8  
Louisiana 488 5.3  740 5.4  
New Jersey 1009 10.9  1666 12.1  
AJCC stage      <0.001 
I 2296 24.8  2739 19.8  
II 5964 64.3  8674 62.8  
III 1018 11.0  2405 17.4  
Size, cm      <0.001 
< 2 3737 40.3  5053 36.6  
≥ 2 5326 57.4  8674 62.8  
Unknown 215 2.3  315 2.3  
Positive lymph node      <0.001 
Negative 4151 44.7  4972 36.0  
Positive 4530 48.8  8195 59.3  
Unknown 597 6.4  651 4.7  
Grade      <0.001 
Well 1189 12.8  1335 9.7  
Moderately 3658 39.4  4928 35.7  
Poorly 3451 37.2  6184 44.8  
Undifferentiated 145 1.6  271 2.0  
Unknown 835 9.0  1100 8.0  
Histology      <0.001 
Ductal 6404 69.0  9893 71.6  
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Lobular 1057 11.4  1471 10.7  
Mixed 1031 11.1  1436 10.4  
Unknown 786 8.5  1018 7.4  
ER/PR status      <0.001 
ER + and/or PR + 6408 69.1  8375 60.6  
ER- and PR- 1734 18.7  3952 28.6  
Unknown 1136 12.2  1491 10.8  
Surgery type/RT      <0.001 
BCS with RT 3297 35.5  4040 29.2  
BCS without RT 1040 11.2  1873 13.6  
Mastectomy 4941 53.3  7905 57.2  
Comorbid conditions       
ASHD 1175 12.7  1609 11.6 0.02 
CHF 430 4.6  562 4.1 0.04 
CVA/TIA 434 4.7  560 4.1 0.02 
Dysrhythmia 972 10.5  1249 9.0 <0.001 
PVD 551 5.9  710 5.1 0.009 
Cardiac disease, other 944 10.2  1264 9.2 0.009 
Abbreviation: AJCC, American Joint Committee on Cancer; ASHD, atherosclerotic heart disease; BCS, 
breast-conserving surgery; CHF, congestive heart failure; CHEMO, chemotherapy; CVA/TIA, 
cerebrovascular accident/transient ischemic attack; ER, estrogen receptor; PR, progesterone receptor; PVD, 
peripheral vascular disease. 
 
4.4.2 Monitoring Renal Function 
Serum Creatinine 
Serum creatinine assessment is the most commonly used test for evaluation of 
kidney function.  
Figure 4-7 displays the cumulative percentage of patients receiving at least one 
serum creatinine assessment during the after-treatment period by adjuvant chemotherapy 
status. Almost 85% of chemotherapy-treated patients and 76% of untreated patients 
received at least one serum creatinine assessment within the first year of follow-up. After 
5 years of follow-up, the cumulative percentages had increased to 97% for patients 
treated with adjuvant chemotherapy and 95% for untreated patients. 
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Figure 4-7 Cumulative percentages of patients receiving at least one serum creatinine 
assessment during the post-treatment period 
 
 
 
Patients treated with adjuvant chemotherapy were more frequently tested for 
serum creatinine level than untreated patients, especially within the first year after 
treatment, and the differences in testing rates between the two patient cohorts steadily 
decreased as follow-up time increased (Table 4-8). The rate of serum creatinine 
assessment for patients who received adjuvant chemotherapy was 4.2 tests per patient in 
the first year post-treatment, 3.5 tests per patient in the second year post-treatment, and 
3.2 tests per patient per year after 2 years post-treatment, compared with a roughly 
constant rate of 2.4 tests per patient per year for no-chemotherapy patients. After 
adjustment for various possible confounders, rates of serum creatinine testing for 
chemotherapy-treated patients, compared with untreated patients, were 68%, 43%, and 
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32% higher in the first year, second year, and after 2 years post-treatment, respectively 
(Table 4-8).  
Urine Albumin 
Although urine albumin assessment is one of the most important tests for 
detecting early kidney damage, it was used less frequently than serum creatinine tests. 
The 1-year cumulative percent of patients receiving at least one urine albumin test was 
less than 5% for both adjuvant chemotherapy-treated and untreated patients (Figure 4-8). 
After 5 years of follow-up, the cumulative percent had increased to 16.2% in 
chemotherapy-treated patients and 15.0% in untreated patients. Even after 10 years of 
follow-up, the cumulative percent reached only 26.6% and 24.7% in treated and untreated 
patients, respectively.   
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Figure 4-8 Cumulative percentage of patients receiving at least one urine albumin 
assessment during the post-treatment period 
 
 
 
The rate of urine albumin assessment was low during each follow-up interval, but 
it increased steadily with increasing follow-up time after treatment for patients in both 
study cohorts, with a higher rate in chemotherapy-treated than in untreated patients 
(Table 4-8). The rates of urine albumin assessment during the first year, second year, and 
after 2 years post-treatment were 61.2, 76.4, and 93.9 per 1,000 person-years, 
respectively, for chemotherapy treated patients, compared with 59.2, 69.4, and 81.2 per 
1,000 person-years for untreated patients. After adjustment for baseline characteristics, 
the differences in rates of urine albumin testing between chemotherapy-treated and 
untreated patients were not statistically significant for the first and second years post-
treatment (Table 4-8). Beyond the first 2 years post-treatment, however, the rate of urine 
albumin testing was 12% higher for chemotherapy-treated than for untreated patients, and 
this difference was significant (RR 1.12, 95% CI 1.03-1.20; P = 0.005).  
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Urine Albumin-to-Creatinine Ratio 
Urine ACR, which requires both albumin and creatinine to be measured in a 
random urine sample, was less frequently used than urine albumin testing to detect early 
kidney damage. The cumulative percentages of patients receiving at least one urine ACR 
test at 1 year, 5 years, and 10 years after treatment were 2.1%, 8.2%, and 14.3%, 
respectively, in patients treated with adjuvant chemotherapy, compared with 2.3%, 7.9%, 
and 13.2% in untreated patients (Figure 4-9).  
 
Figure 4-9 Cumulative percentage of patients receiving at least one urine albumin-to-
creatinine ratio assessment during the post-treatment period  
 
 
 
Rates of urine ACR assessment were slightly lower for patients who received 
adjuvant chemotherapy than for patients who did not during the first and second years 
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4-8). Rates of urine ACR assessment during the first year, second year, and after the first 
2 years post-treatment were 25.5, 32.5, and 42.9 per 1,000 person-years, respectively, for 
chemotherapy-treated patients, compared with 27.2, 33.1, and 33.4 per 1,000 person-
years for untreated patients. After adjustment for baseline characteristics, the differences 
in rates of urine albumin testing between chemotherapy-treated and untreated patients 
were not statistically significant for the first or the second year post-treatment (Table 
4-8). Beyond the first 2 years post-treatment, however, the rate of urine albumin testing 
was 21% higher for chemotherapy-treated than for untreated patients, and this difference 
was significant (RR 1.21, 95% CI 1.08-1.35; P < 0.001).  
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Table 4-8 Assessment of kidney function in surgically treated breast cancer patients during post-treatment period by follow-up 
intervals 
 CHEMO  No CHEMO    
Laboratory tests/Follow-up 
intervals 
Total, n (% 
pts. tested) 
Total tests 
performed Rate*  
Total, n (% 
pts. tested) 
Total tests 
performed Rate*  RR (95% CI)† P 
Serum creatinine           
≤ 1 year 13818 (81.8) 52847 4205.6  9278 (73.0) 21338 2463.3  1.68 (1.54, 1.83) <0.001 
> 1-≤ 2 years 12367 (82.8) 39687 3544.1  8110 (75.3) 18320 2432.3  1.43 (1.30, 1.57) <0.001 
> 2-< 18 years 10607 (92.9) 131408 3240.3  6840 (89.4) 62184 2368.9  1.32 (1.26, 1.39) <0.001 
Urine albumin           
≤ 1 year 13818 (4.6) 769 61.2  9278 (4.4) 513 59.2  1.00 (0.86, 1.18) 0.95 
> 1-≤ 2 years 12367 (5.4) 856 76.4  8110 (5.2) 523 69.4  1.07 (0.92, 1.25) 0.37 
> 2-< 18 years 10607 (14.6) 3808 93.9  6840 (12.9) 2131 81.2  1.12 (1.03, 1.20) 0.005 
Urine ACR           
≤ 1 year 13818 (2.0) 321 25.5  9278 (2.1) 236 27.2  0.90 (0.72, 1.12) 0.33 
> 1-≤ 2 years 12367 (2.4) 364 32.5  8110 (2.6) 249 33.1  0.95 (0.76, 1.17) 0.60 
> 2-< 18 years 10607 (7.6) 1739 42.9  6840 (6.5) 878 33.4  1.21 (1.08, 1.35) <0.001 
* Rate presented as total number of tests performed per 1,000 patient-years. 
†An interval Poisson model was used to estimate the adjusted rate ratio of laboratory testing for kidney disease for patients in the adjuvant chemotherapy-treated 
cohort compared with patients in the untreated cohort. Patient demographic characteristics, comorbid conditions at baseline, and tumor characteristics were 
included in the model. 
Abbreviation: ACR, Albumin-to-creatinine ratio; CHEMO, chemotherapy; CI, confidence interval; RR, rate ratio. 
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Chapter 5 Discussion 
5.1 Summary of Major Findings 
To my knowledge, this is the first population-based study to systematically assess 
the acute and chronic nephrotoxic effects related to use of adjuvant chemotherapy and 
post-treatment kidney function monitoring among elderly breast cancer patients. In this 
study, I found that adjuvant chemotherapy was significantly associated with a 2.7-fold 
increased risk of AKI within 6 months after chemotherapy initiation, although the overall 
incidence rate of AKI was markedly low in this population (16 per 1,000 patient-years in 
chemotherapy-treated patients and 6 per 1,000 patient-years in untreated patients). 
Moreover, each type of chemotherapy was significantly associated with increased risk of 
AKI, with the strongest association for taxane-based chemotherapy, the weakest for a 
CMF regimen, and intermediate association for anthracycline-based and other types of 
chemotherapy. Trastuzumab use was associated with a 6% increased risk of AKI, but this 
association was not statistically significant after adjustment for patient and tumor 
characteristics.  
I found no association between adjuvant chemotherapy and risk of CKD during 
the maximum of 18 years follow-up. Compared with patients who did not receive 
adjuvant chemotherapy, patients who received CMF or “other” chemotherapy were 4% 
more likely to develop CKD, while patients who received anthracyclines and taxanes 
were 6% and 9% less likely to develop CKD, respectively. However, these associations 
were not statistically significant. Trastuzumab use was associated with an 18% increased 
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risk of CKD. This association, however, was not statistically significant after adjustment 
for patient and tumor characteristics.  
During the post-treatment period, serum creatinine level was assessed in elderly 
breast cancer patients at a rate decreasing from 4.2 tests per patient per year within the 
first year after treatment to 3.2 tests per patient per year after 2 years after treatment in 
patients treated with adjuvant chemotherapy, compared with a roughly constant 2.4 tests 
per patient per year in patients not treated with adjuvant chemotherapy. Although the 
strength of association between adjuvant chemotherapy and frequency of serum 
creatinine tests attenuated with increasing follow-up time, the rate of serum creatinine 
testing remained a significant 32% higher for chemotherapy-treated than for untreated 
patients even after 2 years of follow-up after adjustment for patient baseline 
characteristics. In contrast, the rate of urine albumin testing increased steadily with 
increasing follow-up time for both chemotherapy-treated and untreated patients, but at a 
much lower rate than serum creatinine testing, ranging from 59 per 1,000 patient-years in 
the first year of follow-up for untreated patients to 94 per 1,000 patient-years after 2 years 
of treatment for treated patients. The rate of urine albumin testing was not significantly 
different between patients treated and not treated with adjuvant chemotherapy within the 
first 2 years of treatment, but was 12% higher in treated than in untreated patients after 2 
years of treatment. The rate of urine ACR testing was about half the rate of urine albumin 
testing, with no significant difference between treated and untreated patients within the 
first 2 years of follow-up and a 21% increased rate in treated compared with untreated 
patients after 2 years of follow-up.  
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5.2 Comparison with Previous Studies and Interpretation 
5.2.1 Effect of Chemotherapy on Risk of AKI 
The low incidence rate of AKI in elderly breast cancer patients observed in this 
study was consistent with two recent population-based studies despite differences in data 
sources used to identify AKI patients, target populations, and lengths of follow-up.112;113 
In a recent Danish population-based cohort study of 46,880 incident cancer patients of all 
ages diagnosed 1999-2006, Christiansen et al examined the incidence rate and cumulative 
incidence of AKI at 1-year and 5-year follow-up, and found that the 1-year risk of AKI 
was highest among patients with kidney cancer, liver cancer, or multiple myeloma and 
lowest among patients with testis cancer, breast cancer, or malignant melanoma.112 Of 
3,938 breast cancer patients with a baseline creatinine measurement, the 1-year incidence 
rate of AKI, defined as a > 50% increase in serum creatinine compared with baseline 
level, was 48 per 1,000 person-years (95% CI 41-56 per 1,000 person-years) and the 1-
year risk of AKI was 4.5% (95% CI 3.9%-5.2%). This study did not examine the 
incidence rate of AKI in chemotherapy-treated patients or whether the risk of AKI was 
related to chemotherapy treatment.  
Another population-based study by Langeberg et al addressed the incidence of 
AKI in adult breast cancer patients and in patients treated with chemotherapy using a 
large national commercial claims database.113 Among 13,150 women diagnosed with 
breast cancer 2000-2007 and aged 18-64 years at diagnosis with no history of renal 
insufficiency, the cumulative incidence of AKI, defined using at least one inpatient or 
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two outpatient claims with an ICD-9-CM code of 584.XX or 586.XX, within a year after 
cancer diagnosis, was 0.3% in all patients and 1.0% in patients receiving nephrotoxic 
chemotherapy. Although this study did not evaluate the association between 
chemotherapy and risk of AKI with adjustment for patient baseline characteristics, it was 
evident that patients who received chemotherapy had much higher incidence of AKI than 
patients who did not.  
Although several experimental animal studies have shown the nephrotoxic 
potential of doxorubicin107;109;110 and cyclophosphamide,97-102 data on nephrotoxic 
potential in humans is limited; only one case report linking anthracyclines with renal 
failure in humans111 and two case reports showed that nephrotoxicity can occur in cancer 
patients treated with low-dose methotrexate.49;50 Therefore, the strong association 
between adjuvant chemotherapy and risk of AKI observed in the current study may not 
be fully explained by the direct nephrotoxic effect on AKI occurrence. Investigation of 
the distribution of diagnosis codes accompanying the AKI diagnosis code reported on 
hospital claims among AKI patients showed that septicemia was the second most 
frequently coded disease at any position on the hospital claims, presenting in 40% of AKI 
patients who received chemotherapy compared with 17% of AKI patients who did not 
receive chemotherapy. Among patients with AKI coded as secondary diagnosis, 
septicemia was the most frequently coded principal diagnosis in 27% of AKI patients 
treated with chemotherapy compared with 15% of AKI patients not treated. These results 
suggest a possible etiologic pathway; i.e., myelosuppressive side effects of 
chemotherapeutic agents used in the adjuvant setting for breast cancer increased risk for 
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sepsis, which in turns led to AKI. Many chemotherapy agents and regimens 
recommended in the NCCN guidelines for treating breast cancer are myelosuppressive 
and associated with higher risk of infection, as manifested by febrile neutropenia.140 
Patients with infection or febrile neutropenia have markedly increased risk for sepsis 
which is the most common cause of AKI in cancer patients.70   
5.2.2 Effect of Chemotherapy on Risk of CKD 
The null association between adjuvant chemotherapy and risk of CKD 
development in elderly breast cancer patients found in the current study may suggest little 
nephrotoxic effect of the chemotherapeutic agents most commonly used in the treatment 
of breast cancer. Although several experimental animal studies have shown nephrotoxic 
potential of doxorubicin107;109;110 and cyclophosphamide,97-102 only a few case reports 
linked these agents with nephrotoxicity in cancer patients.49;50;111 The null association 
between adjuvant chemotherapy and diagnosis of CKD in elderly breast cancer patients 
was also observed in two sensitivity analyses: 1) initiation of adjuvant chemotherapy 
defined as a time-varying variable; and 2) competing risk analysis with death as a 
competing event for CKD. These sensitivity analyses were performed to evaluate the 
association between adjuvant chemotherapy and risk of CKD from different aspects. The 
analysis with initiation of adjuvant chemotherapy defined as a time-varying variable 
included all 84,018 elderly women with breast cancer who met the study inclusion and 
exclusion criteria to ensure the largest possible sample size. The result showed a non-
significant 4% reduced risk of CKD associated with adjuvant chemotherapy after 
adjustment for potential confounders. The competing risk analysis examined the effect of 
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adjuvant chemotherapy on development of CKD during the time interval when patients 
remained alive. Although patients treated with adjuvant chemotherapy had a 3% 
increased risk of CKD compared with untreated patients after adjustment for patient 
baseline characteristics, this association was not significant.  
Another possible explanation for the null association between adjuvant 
chemotherapy and risk of CKD in elderly breast cancer patients is related to the method 
used to identify CKD patients using ICD-9-CM diagnosis codes in Medicare claims. 
Previous validation studies of claims-based definitions of CKD suggested that the claims-
based method identifies CKD stages 3-5.129;130 If the chemotherapeutic agents most 
commonly used in treating breast cancer likely cause mild (i.e., stages 1-2) damage to 
kidney function, Medicare claims data poorly identify these cases. Therefore, the findings 
in the present study likely reflect a null association between chemotherapy and risk of 
advanced stages of CKD.   
The results from the analyses of the subgroup of patients who received one cycle 
of chemotherapy and matched untreated patients showed a significant 40% increased risk 
of CKD associated with receiving chemotherapy. Adjuvant chemotherapy for breast 
cancer usually requires 4-8 cycles and may last 3-8 months. For patients who received 
treatment for less than 1 week, an adverse event likely prevented them from completing 
the course. Additionally, these patients had more risk factors for CKD (increasing age, 
black race, diabetes, and cardiovascular disease) than patients whose chemotherapy 
treatment lasted more than 1 week. Thus, the observed significant 40% increased risk of 
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CKD in this subgroup may be due to underlying high risk for CKD, and chemotherapy 
treatment increased the likelihood of adverse responses to chemotherapeutic agents.  
The current study demonstrates that increasing age, black race, cardiovascular 
disease, diabetes, and hypertension were associated with greater risk of CKD in elderly 
breast cancer patients. These findings were consistent with prior studies of risk factors for 
CKD.1   
5.2.3 Monitoring Renal Function  
Few studies have examined clinical practice patterns of renal function monitoring 
and the association between adjuvant chemotherapy and rate of renal function monitoring 
in elderly breast cancer patients during the post-treatment period. A study by the USRDS 
examined the trends in 1-year cumulative percent of serum creatinine and urine albumin 
testing in the elderly Medicare population without CKD 2000-2010141 The 1-year 
cumulative percent of patients receiving at least one serum creatinine measurement was 
62% in 2000 and increased to 77% in 2010. Compared with the rate of serum creatinine 
testing in the Medicare population without CKD, serum creatinine assessment in elderly 
women with breast cancer was more frequent; the 1-year cumulative percent of testing 
was 84% in patients treated with adjuvant chemotherapy and 76% in patients not treated. 
This higher rate of serum creatinine testing in breast cancer patients was likely due to 
regular follow-up physical exams indicated by the NCCN and ASCO guidelines. Because 
serum creatinine testing is usually part of a panel of tests in basic or comprehensive 
metabolic panels, frequent assessment of serum creatinine may not necessarily indicate 
active assessment of kidney function during the physical exams.  
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Unlike serum creatinine assessment, urine albumin testing must be ordered 
separately. Therefore, urine albumin testing may represent a true intent to assess kidney 
disease. The USRDS reported that the 1-year cumulative percent of at least one urine 
albumin measurement in the elderly Medicare population without CKD was only 2% in 
2000, increased to 6% in 2004, and reached 10% in 2010.141 For elderly women with 
breast cancer, in contrast, the 1-year cumulative percent of patients receiving at least one 
urine albumin test after completion of treatment was about 5% regardless of 
chemotherapy treatment. These comparisons suggest that elderly women with breast 
cancer did not receive more screening for kidney disease than the general Medicare 
population without CKD.  
The results of the current study comparing the rate of urine albumin testing 
between patients treated and not treated with adjuvant chemotherapy during each follow-
up interval showed that the rate of urine albumin testing was similar for treated and 
untreated patients within the first 2 years of follow-up, but increased by a significant 12% 
for treated patients after the first 2 years of follow-up. This finding may imply that 
treatment and management of the survivor’s primary disease is the clinical focus when 
patients first finish their primary treatment. Although the testing rate in chemotherapy-
treated patients was significantly higher than in untreated patients after 2 years after 
completion of treatment, the rate was markedly low for both treated (94 tests per 1,000 
patient-years) and untreated (81 tests per 1,000 patient-years) patients. The findings of a 
low rate of renal function monitoring regardless of chemotherapy treatment status and no 
additional risk of CKD associated with adjuvant chemotherapy do not provide sufficient 
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evidence for the need for a clinical practice guideline for the surveillance and 
management of nephrotoxicity among elderly women with breast cancer and treated with 
chemotherapy.   
In a subgroup analysis of elderly breast cancer patients with diabetes, the rate of 
urine albumin testing was greatly increased regardless of chemotherapy status, but there 
was no association between adjuvant chemotherapy and increased rate of monitoring in 
each follow-up interval (results are not shown). Since diabetes is an important risk factor 
for CKD, and NKF K/DOQI guidelines recommend assessment of proteinuria yearly in 
adults with type 2 diabetes, these results suggest that CKD surveillance of elderly breast 
cancer patients with diabetes followed the clinical guidelines for the general population at 
risk for CKD. Adjuvant chemotherapy did not impact the active assessment of kidney 
disease to any extent in elderly women with breast cancer.  
5.3 Strengths and Limitations 
This study had several strengths. First, the study population consisted of elderly 
breast cancer patients with Medicare fee-for-service coverage at the time of diagnosis. 
This patient group is usually underrepresented in clinical trials due to comorbid 
conditions or potential survival limitations. Thus, patients included in this study may be 
fairly representative of elderly breast cancer patients. Second, a propensity-matched 
cohort study design may reduce treatment selection bias due to factors that may have 
influenced physicians or patients to choose chemotherapy and may be related to 
outcomes. Third, information on health conditions and associated treatments was nearly 
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complete in Medicare claims data because the Medicare program covers all medical 
services provided to beneficiaries. Fourth, misclassification of chemotherapy treatment, 
laboratory tests, or cancer-related clinical factors was likely minimal because 1) 
information on cancer-related clinical factors provided by SEER registries was of high 
quality; and 2) facilities/providers are motivated to accurately report chemotherapy drug 
costs and administration fees and laboratory tests and procedures in order to receive 
reimbursement. Finally, the maximum of 18 years follow-up allowed for more complete 
assessment of CKD status and adequate evaluation of post-treatment renal function 
monitoring, which are almost impossible to evaluate in clinical trials of shorter duration.  
The limitations of the study should be noted. First, it is a retrospective 
observational study. Because chemotherapy treatment was not randomly assigned, a 
causal relationship between chemotherapy use and the risk of AKI and CKD cannot be 
inferred. Although propensity matching was used to balance baseline characteristics in 
patients receiving and not receiving chemotherapy, a propensity score-matched cohort 
study is not equivalent to a randomized clinical trial. Residual confounding likely exists 
due to unknown and/or unmeasured confounding variables.  
Second, misclassifications of AKI and CKD based on Medicare claims are also 
concerns. Perfect specificity and imperfect sensitivity of a disease ascertainment will not 
bias the estimated measure of association, although the statistical power for detecting a 
significant association may be reduced. In the presence of imperfect specificity, however, 
the estimated measure of association will be biased towards the null hypothesis.142 Since 
both AKI and CKD are uncommon events among cancer patients,4 the degree of 
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underestimation will be influenced more by the specificity than by the sensitivity of 
ascertainment of AKI and CKD. As described in Sections 3.4.2 and 3.4.3, the specificity 
of the claims-based definitions of AKI and CKD used in this study was likely to be 
greater than 91% and 93%, respectively, but whether they were close to 100% is not 
clear. Therefore, given such misclassification was likely non-differential, the estimated 
associations between chemotherapy use and the risk of AKI and CKD may be biased 
towards to the null hypothesis.  
Third, Medicare claims contain limited information on the dosage and intensity of 
chemotherapy and biochemical data to determine CKD stage. Therefore, presence of a 
dose-response relationship between adjuvant chemotherapy and development of CKD 
and whether adjuvant chemotherapy had adverse effects on the development of early 
CKD could not be addressed in this study.  
Fourth, the statistical power to examine the associations between chemotherapy 
regimen and the risks of AKI and CKD was likely limited. 
Finally, the study sample was restricted to elderly incident breast cancer patients 
with stages I-III and enrolled in Medicare fee-for-service, so it is uncertain that the 
findings can be extrapolated to younger patients, patients with stage 0 or stage IV, or 
patients not enrolled in Medicare fee-for-service. 
5.4 Implications 
Results from the current study have several important implications for clinicians 
treating elderly breast cancer patients. First, most chemotherapeutic agents used to treat 
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breast cancer in the adjuvant setting may not have a direct nephrotoxic effect. Instead, 
these agents cause myelosuppression, which increases the risk of infection and 
subsequent AKI. Therefore, prevention of serious complications of chemotherapy 
including sepsis and infection is important in preventing AKI for patients who receive 
adjuvant chemotherapy. Second, the findings of the current study do not suggest that 
adjuvant chemotherapy for breast cancer was associated with increased long-term risk of 
advanced CKD. Therefore, when clinicians discuss with their patients the potential risk of 
development of CKD after chemotherapy treatment and the choice of chemotherapy 
treatment, mainly the patient’s comorbid conditions and other risk factors for CKD 
should be considered. Other risk factors for CKD should be managed appropriately based 
on existing guidelines. Finally, the findings of no statistically significant association 
between adjuvant chemotherapy and risk of CKD and the rate of renal function 
monitoring during the post-treatment period for elderly women with breast cancer do not 
provide sufficient evidence to recommend clinical practice guidelines to routinely screen 
for CKD after adjuvant chemotherapy treatment in elderly breast cancer patients. 
5.5 Future Research 
One important area for future research is to investigate whether trastuzumab use is 
associated with increased risk of CKD. Trastuzumab is a recombinant DNA-derived 
humanized monoclonal antibody that binds to HER2, the human epidermal growth factor 
receptor 2 protein. It was first approved by the FDA to treat patients with metastatic 
breast cancer who had HER2-positive and node-positive tumors. In November 2006, 
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FDA approval was expanded to the adjuvant setting combining trastuzumab with 
chemotherapy to treat patients with early stage, node-positive, and HER2-overexpressing 
breast cancer. In January 2008, FDA approval was revised to include trastuzumab for use 
as stand-alone treatment (without chemotherapy) in the adjuvant setting. Though use of 
trastuzumab remains limited to patients with HER2-positive breast cancer, it could be 
prescribed to patients regardless of lymph node involvement. Along with FDA approval 
of trastuzumab use in the adjuvant setting, trastuzumab use for early stage breast cancer 
has been increasing since 2005. Results in the current study showed that trastuzumab use 
in the adjuvant setting for elderly women with breast cancer increased rapidly from 
12.5% in 2005 to about 20% in 2008. Though trastuzumab could improve disease-free 
survival for breast cancer patients, studies have shown that breast cancer patients treated 
with trastuzumab chemotherapy are at increased risk for heart failure and/or 
cardiomyopathy compared with women not treated with chemotherapy.143 NCCN 
guidelines recommend cardiac monitoring for trastuzumab-containing regimens at 
baseline and at 3, 6, and 9 months. The current study found that trastuzumab was 
associated with an 18% increased risk of CKD among elderly breast cancer patients 
treated with chemotherapy. Due to the small sample size of patients using trastuzumab 
(about 800) and limited follow-up time, statistical power was not adequate to fully test an 
association. With increased trastuzumab use in the adjuvant setting for early stage breast 
cancer and the growing number of cancer survivors and CKD patients in the U.S., 
investigation of the long-term effect of trastuzumab on risk of CKD is warranted.  
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Findings from the current study did not suggest an association between adjuvant 
chemotherapy and risk of CKD in elderly women with breast cancer, nor did the findings 
provide evidence to recommend clinical practice guidelines to routinely screen for CKD 
after adjuvant chemotherapy treatment in elderly breast cancer patients. However, with 
the development of new chemotherapeutic and biologic agents that may be potentially 
nephrotoxic and the growing number of cancer survivors and CKD patients in the U.S, 
studies of CKD as a late effect of cancer treatment for other solid tumors commonly 
treated with known or potential nephrotoxic agents and are warranted.  
Another potential area to consider for future research is using an instrumental 
variable (IV) approach to reduce bias caused by unknown and/or unmeasured 
confounders that could not be addressed in this retrospective observational study. The IV 
approach has been recently introduced to medical research, and application of an IV may 
reduce bias caused by measured and unmeasured confounders in observational studies. 
However, the major limitation of the IV method is that a suitable IV is difficult to find 
due to the strong assumptions,144 and IV studies require large sample sizes.  
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Chapter 6 Conclusions 
This body of work is, to my knowledge, the first population-based observational 
study to systematically examine the association of adjuvant chemotherapy with risks of 
AKI and CKD and rate of renal function monitoring during the post-treatment period 
among elderly breast cancer patients. Several key findings include:  
• Adjuvant chemotherapy and risk of AKI 
o Although the overall incidence rate of AKI was quite low in elderly 
women with breast cancer (16/1,000 person-years in patients treated 
with adjuvant chemotherapy and 6/1,000 person-years in patients not 
treated), adjuvant chemotherapy was significantly associated with a 2.7-
fold increased risk of AKI within 6 months after chemotherapy initiation 
(95% CI 1.8-4.1; P < 0.001). 
o The strength of association varied among the main chemotherapy 
regimens, and was strongest for taxane-based chemotherapy (HR 4.2, 
95% CI 2.2-2.8; P < 0.001), weakest for CMF regimen (HR 2.2, 95% CI 
1.3-3.8; P = 0.004, and intermediate for anthracycline-based (HR 2.5, 
95% CI 1.6-4.1; P < 0.001) and other types of chemotherapy (HR 3.0, 
95% CI 1.5-6.2; P = 0.003). 
o Septicemia was the second most commonly diagnosed disease in 
patients who received chemotherapy and developed AKI, representing 
40% of these cases, while it occurred in only 17% of patients with AKI 
who did not receive chemotherapy. 
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• Adjuvant chemotherapy and risk of CKD 
o Adjuvant chemotherapy was not associated with increased risk of CKD 
among elderly women with breast cancer (HR 1.00, 95% CI 0.93-1.07; 
P = 0.91). Although the association varied among major chemotherapy 
regimens, none of the associations were statistically significant.  
o Trastuzumab use was associated with an 18% increased risk of CKD 
among elderly women with breast cancer who received adjuvant 
chemotherapy. This association, however, was not statistically 
significant after adjustment for patient and tumor characteristics.  
• Adjuvant chemotherapy and rate of serum creatinine assessment 
o Serum creatinine level was frequently assessed in elderly breast cancer 
patients, especially those receiving chemotherapy. For patients treated 
with adjuvant chemotherapy, the rate of testing was as high as 4.2 tests 
per patient per year within the first year of follow-up and decreased to 
3.2 tests per patient per year after 2 years of treatment. By contrast, the 
rate was roughly constant at 2.4 tests per patient per year during the 
post-treatment period for no-chemotherapy patients. 
o Although the strength of association between adjuvant chemotherapy 
and frequency of serum creatinine testing attenuated with increasing 
follow-up time, the rate remained a significant 32% higher for patients 
treated with chemotherapy (RR 1.32, 95% CI 1.26-1.39; P < 0.001) than 
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for untreated patients even after 2 years of follow-up after adjustment 
for patient baseline characteristics.  
• Adjuvant chemotherapy and rate of urine albumin assessment 
o The rate of urine albumin testing increased steadily with increasing 
follow-up time for both chemotherapy-treated and untreated patients, 
but was much lower than the rate of serum creatinine testing, ranging 
from 59/1,000 patient-years in first year of follow-up for untreated 
patients to 94/1,000 patient-years after 2 years of treatment for treated 
patients.  
o The rate of urine albumin testing was not significantly different between 
patients treated and not treated with adjuvant chemotherapy within the 
first 2 years of treatment, but was 12% higher in treated patients after 2 
years of treatment (RR 1.12, 95% CI 1.03-1.20; P = 0.005).  
• Adjuvant chemotherapy and rate of urine ACR assessment 
o The rate of urine ACR testing was about half the rate of urine albumin 
testing for both chemotherapy-treated and untreated patients. 
o Within the first 2 years of follow-up, there were no significant 
differences in rate of ACR testing between patients treated and not 
treated with adjuvant chemotherapy. After 2 years of follow-up, the rate 
of testing for treated patients was 21% higher than for untreated patients 
(RR 1.21, 95% CI 1.08-1.35; P < 0.001). 
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In conclusion, this body of work suggests that the increased risk of AKI 
associated with adjuvant chemotherapy among elderly women with breast cancer is likely 
explained by the following etiology pathway: myelosuppressive chemotherapeutic agents 
increased the risk of infection/neutropenia, which increased the risk of septicemia and 
subsequent risk of AKI. This finding highlights the importance of preventing serious 
complications of chemotherapy, including infection and sepsis, in preventing AKI for 
patients who received adjuvant chemotherapy. Additionally, adjuvant chemotherapy in 
elderly women with breast cancer may not impose additional risk for CKD. This finding 
suggests that patients’ underlying risk factors for CKD such as diabetes, hypertension, 
etc. should be considered in the discussions between clinicians and patients regarding 
potential risk of CKD development after chemotherapy treatment and choice of 
chemotherapy treatment. Finally, although renal function should be assessed prior to each 
cycle for potential dose modification for several nephrotoxic agents, the findings do not 
provide sufficient evidence of the need for a clinical practice guideline for CKD 
screening among elderly breast cancer survivors treated with adjuvant chemotherapy. 
However, with the development of new chemotherapeutic agents and the growing 
number of cancer survivors and CKD patients in the U.S., studies may be needed of CKD 
as a late effect of chemotherapy for other solid tumors and of the cost-benefit of clinical 
practice guidelines on surveillance and nephrotoxic management in survivors of other 
type of cancers diagnosed and treated in adults. 
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Appendices 
 
Appendix A. Administrative Codes Used to Identify Cancer Treatment from Medicare 
Claims 
 
Table A.1 Administrative Codes Used to Identify Receipt of Any Chemotherapy  
Type of codes Codes 
ICD-9 procedure codes for administration 99.25 
CPT codes for administration 96400-96549 excluding 96402  
HCPCS codes for administration C8953-C8955, G0355-G0362 excluding 
G0356, Q0083-Q0085 
ICD-9 diagnosis code  V58.1, V66.2, V67.2 
Revenue codes 0331; 0332; 0335 
DRG codes 410, 492 
HCPCS codes for chemo agents A9523, A9534, A9542-A9545, C1081, 
C1083, C1166, C1178, C9017, C9110, 
C9117, C9118, C9120, C9414, C9415, 
C9417-C9427, C9429, C9431-C9433, 
C9437, C9440, G3001, J8510, J8520, 
J8521, J8530, J8560, J8600, J8610, J8700, 
J8999, J9000-J9999 (excluding J9217-
J9219, J9202, J9225, J9395), S0087, 
S0108, S0178, S0179 
 
 
 123 
 
Table A.2 HCPCS Codes Used to Identify Specific Agents Commonly used for Breast 
Cancer from Medicare Claims 
Chemotherapeutic agent HCPCS codes 
5-FU J9190 
Doxorubicin C9415; J9000; J9001 
Epirubicin J9178 
Cyclophosphamide C9420, C9421, J8530, J9070-J9097 
Methotrexate J8610, J9250, J9260 
Paclitaxel 
Docetaxel 
C9431, J9264, J9265 
J9170 
Trastuzumab J9355 
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Appendix B. ICD-9-CM Codes Used to Identify Specific Conditions 
 
Table B.1 ICD-9-CM Codes Used to Identify Acute Kidney Injury 
Codes Description 
ICD-9-CM Diagnosis Code  
584.5 Acute kidney injury with lesion of tubular necrosis 
584.6 Acute kidney injury with lesion of cortical necrosis 
584.7 Acute kidney injury with lesion of renal medullary 
necrosis 
584.8 Acute kidney injury with other specified pathologic 
lesion 
584.9 Acute kidney injury, unspecified 
V45.1 Renal dialysis status 
V56.0 Extracorporeal dialysis 
V56.1 Fitting and adjustment of extracorporeal dialysis catheter 
ICD-9-CM Procedure Code  
39.95 Hemodialysis 
54.98 Peritoneal dialysis 
CPT Code  
90935 Hemodialysis procedure with single physician evaluation 
90937 Hemodialysis procedure requiring repeated evaluation(s) 
with or without substantial revision of dialysis 
prescription 
90945 Dialysis procedure other than hemodialysis with single 
physician evaluation 
90947 Procedure other than hemodialysis requiring repeated 
physician evaluations, with or without substantial 
revision of dialysis prescription 
Revenue code  
0800 Inpatient renal dialysis, general classification 
0801 Inpatient hemodialysis 
0802 Inpatient peritoneal (Non-CAPD) 
0803 Inpatient continuous ambulatory peritoneal dialysis 
(CAPD) 
0804 Inpatient continuous cycling peritoneal dialysis (CCPD) 
0809 Other inpatient dialysis 
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Table B.2 ICD-9-CM Diagnosis Codes Used to Identify Chronic Kidney Disease 
Code Description 
016.0 Renal tuberculosis 
095.4   Syphilis of kidney 
189.0   Malignant neoplasm of kidney 
189.9   Malignant neoplasm, urinary organ, site unspecified 
223.0  Benign neoplasm of kidney 
236.91  Neoplasm of uncertain behavior of kidney and ureter 
250.4 Diabetes with renal manifestations 
271.4 Renal glycosuria 
274.1X Gouty nephropathy 
283.11 Hemolytic-uremic syndrome 
403.X1 Hypertensive renal disease with renal failure 
404.X2 Hypertensive heart and renal disease with renal failure 
404.X3 Hypertensive heart and renal disease with CHF, renal failure 
440.1 Atherosclerosis of renal artery 
442.1 Other aneurysm of renal artery 
447.3 Hyperplasia of renal artery 
572.4 Hepatorenal syndrome 
580 Acute glomerulonephritis 
581 Nephrotic syndrome 
582 Chronic glomerulonephritis 
583 Nephritis & nephropathy, not specified as acute or chronic  
584 Acute renal failure 
585 Chronic renal failure 
586 Renal failure, unspecified 
587 Renal sclerosis 
588 Disorders resulting from impaired renal function 
591 Hydronephrosis 
642.1 Hypertension secondary to renal disease, complicating pregnancy 
646.2 Unspecified renal disease in pregnancy, without hypertension 
753.12 Polycystic kidney, unspecified type 
753.13 Polycystic kidney, autosomal dominant 
753.14 Polycystic kidney, autosomal recessive 
753.15 Renal dysplasia 
753.16 Medullary cystic kidney 
753.17 Medullary sponge kidney 
753.19 Other specified cystic kidney disease 
753.2X Obstructive defects of renal pelvis and ureter 
794.4 Abnormal renal function test 
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Table B.3 ICD-9-CM diagnosis codes used to identify comorbid conditions 
Condition ICD-9-CM Diagnosis Codes 
Atherosclerotic Heart Disease 
(ASHD) 
410-414; V45.18; V45.82 
Cerebrovascular 
Accidents/Transient Ischemic 
Attacks (CVA/TIA) 
430-438 
Chronic Obstructive Pulmonary 
Disease (COPD) 
491-494; 496; 510 
Congestive Heart Failure (CHF) 398.91; 422; 425; 428; 402.x1; 404.x1; 404.x3; 
V42.1 
Diabetes Mellitus (DM) 250; 357.2; 362.0x; 366.41 
Cardiac dysrhythmia 426-427; V45.0; V53.3 
Gastro-intestinal disease (GI) 456.0-456.2; 530.7; 531-534; 569.84; 569.85; 578 
Liver disease 570; 571; 572.1; 572.4; 573.1-573.3; V42.7 
Cardiac disease, other 420-421; 423-424; 429; 785.0-785.3; V42.2; 
V43.3 
Peripheral Vascular Disease (PVD) 440-444; 447; 451-453; 557 
Anemia 280-285 
Hypertension 362.11; 401.x-405.x; 437.2 
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Table B.4 ICD-9-CM diagnosis codes used to identify cancer in situ, primary cancer, and 
metastatic cancer 
Condition ICD-9-CM Diagnosis Codes 
Cancer in situ  
Digestive organs 230 
Respiratory systems 231 
Skin 232 
Breast 2330 
Genitourinary system 2331-2339 
Other and unspecified sites 234 
  
Primary cancer site  
Head and Neck  140-14999 
Esophagus  150-15099 
Stomach and Small Intestine  151-15299 
Colon and Rectum  153-15489 
Liver  155-15529 
Gallbladder  156-15699 
Pancreas  157-15799 
Retroperitoneum and Peritoneum  158-15899 
Spleen  159-15999 
Lung  162-16399 
Other Respiratory  160-16199, 164-16599 
Bone  170-17099 
Connective and Soft Tissue 171-17199 
Melanoma  172-17299 
Female Breast  174-17499 
Male Breast  1750 or 1759 
Sarcoma  176-17699 
Gynecologic  179-18499 
Prostate  185 
Other Genitourinary 186-18999 
Central Nervous System  190-19299 
Endocrine 193-19499 
Non-Hodgkins Lymphoma  200-20099; 202-20299 
Hodgkins Lymphoma  201-20199 
Multiple Myeloma 203-20380 
Leukemia  204-20891 
Ill Defined 195-19599; 199-19999 
  
Metastasis sites  
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Lymph nodes 196 
Respiratory system 1970-1973 
Digestive system 1974-1978 
Urinary system 1980-1981 
Skin 1982 
Nervous system 1983-1984 
Bone and bone marrow 1985 
Ovary 1986 
Adrenal Gland 1987 
Other specified sites 1988 
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Table B.5 International Classification of Diseases, Ninth Revision, Clinical Modification 
Codes (ICD-9-CM) Procedure Codes and CPT Codes Used for Defining Surgery Type 
Codes Description 
Mastectomy  
ICD-9 codes  
85.41 Unilateral simple mastectomy 
85.42 Bilateral simple mastectomy 
85.43 Unilateral extended simple mastectomy 
85.44 Bilateral extended  simple mastectomy 
85.45 Unilateral radical mastectomy 
85.46 Bilateral radical mastectomy 
85.47 Unilateral extended radical mastectomy 
85.48 Bilateral extended radical mastectomy 
CPT codes  
19180, 19303 Mastectomy, simple, complete  
19182, 19304 Mastectomy, subcutaneous 
19200, 19305 Mastectomy, radical, including pectoral muscles, axillary 
lymph nodes 
19220, 19306 Mastectomy, radical, including pectoral muscles, axillary and 
internal mammary lymph nodes (Urban type operation) 
19240, 19307 Mastectomy, radical, including axillary lymph nodes, with or 
without pectoralis minor muscles, but excluding pectoralis 
major muscle  
  
Breast Conserving Surgery 
ICD-9 codes  
85.21 Local excision of lesion of breast 
85.22 Resection of quadrant of breast 
85.23 Subtotal mastectomy 
CPT codes  
19120 Local excision 
19125 Excision of breast lesion identified by preoperative placement 
of radiological marker, open; signle lesion 
19160, 19301 Mastectomy, partial (eg, lumpectomy, tylectomy, 
quadrantectomy, segmentectomy) 
19162, 19302 Mastectomy, partial with axillary lymphadenectomy 
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Appendix C. Current Procedural Terminology Codes Used to Identify Assessment of 
Renal Function 
 
Test Codes 
Blood test  
Serum Creatinine 80047-80050, 80053, 80054, 80069, and 82565 
Urine test  
Urine albumin 82042, 82043, 82044, and 84156 
ACR* 82042 and 82570, or 82043 and 82570 on the same claim 
*ACR, urinary albumin to creatinine ratio. 
 
 
 
 
